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I. Introduction
The American College of Cardiology (ACC)/American Heart
Association (AHA) Task Force on Practice Guidelines regu-
larly reviews existing guidelines to determine when an update
or full revision is needed. This process gives priority to areas
where major changes in text, particularly recommendations,
are required on the basis of new understanding of evidence.
Minor changes in verbiage and references are discouraged.
The ACC/AHA Guidelines for the Evaluation and Manage-
ment of Chronic Heart Failure in the Adult published in 2001
have now been updated. The full-text guidelines incorporat-
ing the updated material are e-published in the Journal of the
American College of Cardiology and Circulation on the ACC
Web site (www.acc.org) and the AHA Web site (www.ameri-
canheart.org) in 2 versions: a version highlighting the
changes in recommendations (i.e., deleted text struck
through, new text underlined) from the 2001 guideline to the
2005 guideline and a “clean” version that incorporates all
changes in the recommendations. (The “track change” ver-
sion only highlights changes to the recommendations; it does
not show changes to supporting text, tables, or figures.) This
article describes the major areas of change reflected in the
update. Please note we have changed the Table of Contents
headings in the 2001 guidelines from roman numerals to
unique identifying numbers. Interested readers are referred to
the full-text guideline to completely understand the context of
these changes.
Heart failure (HF) is a major and growing public health
problem in the United States. Approximately 5 million
patients in this country have HF, and more than 550 000
patients are diagnosed with HF for the first time each year (1).
The disorder is the primary reason for 12 to 15 million office
visits and 6.5 million hospital days each year (2). From 1990
to 1999, the annual number of hospitalizations has increased
from approximately 810 000 to over 1 million for HF as a
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primary diagnosis and from 2.4 to 3.6 million for HF as a
primary or secondary diagnosis (3). In 2001, nearly 53 000
patients died of HF as a primary cause. The number of HF
deaths has increased steadily despite advances in treatment, in
part because of increasing numbers of patients with HF due to
better treatment and “salvage” of patients with acute myocar-
dial infarctions (MIs) earlier in life (1).
Heart failure is primarily a condition of the elderly (4), and
thus the widely recognized “aging of the population” also
contributes to the increasing incidence of HF. The incidence
of HF approaches 10 per 1000 population after age 65 (1) and
approximately 80% of patients hospitalized with HF are more
than 65 years old (5). Heart failure is the most common
Medicare diagnosis-related group (i.e., hospital discharge
diagnosis), and more Medicare dollars are spent for the
diagnosis and treatment of HF than for any other diagnosis
(6). It has been estimated that in 2005, the total direct and
indirect cost of HF in the U.S. will be equal to $27.9 billion
(1). In the United States, approximately $2.9 billion annually
is spent on drugs for the treatment of HF (1).
The ACC and the AHA first published guidelines for the
evaluation and management of HF in 1995 (7) and published
revised guidelines in 2001 (8). Since that time, a great deal of
progress has been made in the development of both pharma-
cological and nonpharmacological approaches to treatment
for this common, costly, disabling, and potentially fatal
disorder. Available treatments have increased, but this in-
crease has rendered clinical decision making far more com-
plex. The timing and sequence of initiating treatments and the
appropriateness of prescribing them in combination are un-
certain. The increasing recognition of the existence of clinical
HF in patients with a normal ejection fraction (EF) has also
led to heightened awareness of the limitations of evidence-
based therapy for this important group of patients. For these
reasons, the 2 organizations believed that it was appropriate
to reassess and update these guidelines, fully recognizing that
the optimal therapy of HF remains a work in progress and that
future advances will require that the guideline be updated
again.
In formulating the 2001 document, the writing committee
decided to take a new approach to the classification of HF,
one that emphasized both the development and progression of
the disease. In doing so, the 2001 document identified 4
stages involved in the development of the HF syndrome. The
first 2 stages (A and B) are clearly not HF but are an attempt
to help healthcare providers identify patients early who are at
risk for developing HF. Stages A and B patients are best
defined as those with risk factors that clearly predispose
toward the development of HF. For example, patients with
coronary artery disease, hypertension, or diabetes mellitus
who do not yet demonstrate impaired left ventricular (LV)
function, hypertrophy, or geometric chamber distortion
would be considered Stage A, whereas patients who are
asymptomatic but demonstrate LV hypertrophy (LVH) and/or
impaired LV function would be designated as Stage B. Stage
C then denotes patients with current or past symptoms of HF
associated with underlying structural heart disease (the bulk
of patients with HF), and Stage D designates patients with
truly refractory HF who might be eligible for specialized,
advanced treatment strategies such as mechanical circulatory
support, procedures to facilitate fluid removal, continuous
inotropic infusions, or cardiac transplantation or other inno-
vative or experimental surgical procedures, or for end-of-life
care, such as hospice.
This classification recognizes that there are established risk
factors and structural prerequisites for the development of HF
and that therapeutic interventions introduced even before the
appearance of LV dysfunction or symptoms can reduce the
population morbidity and mortality of HF. This classification
system is intended to complement but in no way to replace the
New York Heart Association (NYHA) functional classifica-
tion, which primarily gauges the severity of symptoms in
patients who are in Stage C or D. It has been recognized for
many years that the NYHA functional classification reflects a
subjective assessment by a healthcare provider and can
change frequently over short periods of time. It has also been
recognized that the treatments used may not differ signifi-
cantly across the classes. Therefore, the committee believed
that a staging system was needed that would reliably and
objectively identify patients during the course of their devel-
oping disease and that would be linked to treatments uniquely
appropriate at each stage of illness. According to this new
staging approach, patients would only be expected to either
not advance at all or to advance from one stage to the next,
unless progression of the disease was slowed or stopped by
treatment, and spontaneous reversal of this progression would
be considered unusual. For instance, although symptoms
(NYHA class) might vary widely over time (in response to
therapy or to progression of disease) in a patient who has
already developed the clinical syndrome of HF (Stage C), the
patient could never return to Stage B (never had HF), and
therapies recommended for Stage C will be appropriate even
if this patient is in NYHA class I. This new classification
scheme adds a useful dimension to our thinking about HF that
is similar to that achieved by staging or risk assessment
systems for other disorders (e.g., those used in the approach
to cancer).
A classification of recommendation and level of evidence
have been assigned to each recommendation. Classification
of recommendations and levels of evidence are expressed in
the ACC/AHA format as follows. Please refer to Table 1 in
the full-text guidelines for more details.
Classification of Recommendations
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure/therapy
is beneficial, useful, and/or effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the useful-
ness/efficacy of a procedure/therapy.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy is not
useful/effective and in some cases may be
harmful.
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Level of Evidence
Level of Evidence A: Data are derived from multiple random-
ized clinical trials or meta-analyses.
Level of Evidence B: Data are derived from a single random-
ized trial, or nonrandomized studies.
Level of Evidence C: Only consensus opinion of experts, case
studies, or standard of care.
This document focuses on the prevention of HF and on the
evaluation and management of chronic HF in the adult patient
with normal or reduced LVEF. It specifically did not consider
acute HF, which might merit a separate set of guidelines and
is addressed in part in the ACC/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial In-
farction (9) and the ACC/AHA 2002 Guideline Update for
the Management of Patients with Unstable Angina and
Non-ST Elevation Myocardial Infarction (10). We have also
excluded HF in children, both because the underlying causes
of HF in children differ from those in adults and because none
of the controlled trials of treatments for HF have included
children. We have not considered the management of HF due
to primary valvular disease [see ACC/AHA Guidelines on the
Management of Patients With Valvular Heart Disease (11)]
or congenital malformations, and we have not included
recommendations for the treatment of specific myocardial
disorders (e.g., hemochromatosis, sarcoidosis, or
amyloidosis).
The various therapeutic strategies described in this docu-
ment can be viewed as a checklist to be considered for each
patient in an attempt to individualize treatment for an evolv-
ing disease process. Every patient is unique, not only in terms
of his or her cause and course of HF, but also in terms of his
or her personal and cultural approach to the disease. Guide-
lines can only provide an outline for evidence-based deci-
sions or recommendations for individual care; these guide-
lines are meant to provide that outline.
All of the recommendations in this guideline update were
written in full sentences that express a complete thought, such
that a recommendation, even if separated and presented apart
from the rest of the document, would still convey the full intent
of the recommendation. It is hoped that this will increase
readers’ comprehension of the guidelines. The rewritten recom-
mendations appear under their respective headings.
Use of boldfaced type in the recommendations shows
where the intent of the recommendations has changed
from the 2001 guidelines.
II. Characterization of HF as a
Clinical Syndrome
A. Definition of HF
Heart failure is a complex clinical syndrome that can result
from any structural or functional cardiac disorder that impairs
the ability of the ventricle to fill with or eject blood. The
cardinal manifestations of HF are dyspnea and fatigue, which
may limit exercise tolerance, and fluid retention, which may
lead to pulmonary congestion and peripheral edema. Both
abnormalities can impair the functional capacity and quality
of life of affected individuals, but they do not necessarily
dominate the clinical picture at the same time. Some patients
have exercise intolerance but little evidence of fluid retention,
whereas others complain primarily of edema and report few
symptoms of dyspnea or fatigue. Because not all patients
have volume overload at the time of initial or subsequent
evaluation, the term “heart failure” is preferred over the older
term “congestive heart failure.”
The clinical syndrome of HF may result from disorders of
the pericardium, myocardium, endocardium, or great vessels,
but the majority of patients with HF have symptoms due to an
impairment of LV myocardial function. Heart failure may be
associated with a wide spectrum of LV functional abnormal-
ities, which may range from patients with normal LV size and
preserved EF to those with severe dilatation and/or markedly
reduced EF. In most patients, abnormalities of systolic and
diastolic dysfunction coexist, regardless of EF. Patients with
normal EF may have a different natural history and may
require different treatment strategies than patients with re-
duced EF, although such differences remain controversial
(see Section 4.3.2 in the full-text guidelines).
Coronary artery disease, hypertension, and dilated cardiomy-
opathy are the causes of HF in a substantial proportion of
patients in the Western world. As many as 30% of patients with
dilated cardiomyopathy may have a genetic cause (12). Valvular
heart disease is still a common cause of HF. In fact, nearly any
form of heart disease may ultimately lead to the HF syndrome.
It should be emphasized that HF is not equivalent to
cardiomyopathy or to LV dysfunction; these latter terms
describe possible structural or functional reasons for the
development of HF. Instead, HF is defined as a clinical
syndrome that is characterized by specific symptoms (dys-
pnea and fatigue) in the medical history and signs (edema,
rales) on the physical examination. There is no single diag-
nostic test for HF because it is largely a clinical diagnosis that
is based on a careful history and physical examination.
B. Heart Failure as a Symptomatic Disorder
The approach that is most commonly used to quantify the
degree of functional limitation imposed by HF is one first
developed by the NYHA. This system assigns patients to 1 of
4 functional classes, depending on the degree of effort needed
to elicit symptoms: patients may have symptoms of HF at rest
(class IV), on less-than-ordinary exertion (class III), on
ordinary exertion (class II), or only at levels of exertion that
would limit normal individuals (class I). Although the func-
tional class tends to deteriorate over periods of time, most
patients with HF do not typically show an uninterrupted and
inexorable worsening of symptoms. Instead, the severity of
symptoms characteristically fluctuates even in the absence of
changes in medications, and changes in medications and diet
can have either favorable or adverse effects on functional
capacity in the absence of measurable changes in ventricular
function. Some patients may demonstrate remarkable recov-
ery, sometimes associated with improvement in structural and
functional abnormalities. Usually, sustained improvement is
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associated with drug therapy, and that therapy should be
continued indefinitely.
The mechanisms responsible for the exercise intolerance of
patients with chronic HF have not been defined clearly.
Although HF is generally regarded as a hemodynamic disor-
der, many studies have indicated that there is a poor relation
between measures of cardiac performance and the symptoms
produced by the disease. Patients with a very low EF may be
asymptomatic, whereas patients with preserved LVEF may
have severe disability. The apparent discordance between EF
and the degree of functional impairment is not well under-
stood but may be explained in part by alterations in ventric-
ular distensibility, valvular regurgitation, pericardial restraint,
cardiac rhythm, conduction abnormalities, and right ventric-
ular function (12). In addition, in ambulatory patients, many
noncardiac factors may contribute substantially to exercise
intolerance. These factors include but are not limited to
changes in peripheral vascular function, skeletal muscle
physiology, pulmonary dynamics, neurohormonal and reflex
autonomic activity, and renal sodium handling. The existence
of these noncardiac factors may explain why the hemody-
namic improvement produced by therapeutic agents in pa-
tients with chronic HF may not be immediately or necessarily
translated into clinical improvement. Although pharmacolog-
ical interventions may produce rapid changes in hemodynam-
ic variables, signs and symptoms may improve slowly over
weeks or months or not at all.
C. Heart Failure as a Progressive Disorder
Left ventricular dysfunction begins with some injury to, or
stress on, the myocardium and is generally a progressive
process, even in the absence of a new identifiable insult to the
heart. The principal manifestation of such progression is a
change in the geometry and structure of the LV, such that the
chamber dilates and/or hypertrophies and becomes more
spherical—a process referred to as cardiac remodeling. This
change in chamber size and structure not only increases the
hemodynamic stresses on the walls of the failing heart and
depresses its mechanical performance but may also increase
regurgitant flow through the mitral valve. These effects, in
turn, serve to sustain and exacerbate the remodeling process.
Cardiac remodeling generally precedes the development of
symptoms (occasionally by months or even years), continues
after the appearance of symptoms, and contributes substan-
tially to worsening of symptoms despite treatment. Progres-
sion of coronary artery disease, diabetes mellitus, hyperten-
sion, or the onset of atrial fibrillation may also contribute to
the progression of HF. The development of structural abnor-
malities can have 1 of 3 outcomes: 1) patients die before
developing symptoms (in stage A or B), 2) patients develop
symptoms controlled by treatment, or 3) patients die of
progressive HF. Sudden death can interrupt this course at any
time.
Although several factors can accelerate the process of LV
remodeling, there is substantial evidence that the activation of
endogenous neurohormonal systems plays an important role in
cardiac remodeling and thereby in the progression of HF.
Patients with HF have elevated circulating or tissue levels of
norepinephrine, angiotensin II, aldosterone, endothelin, vaso-
pressin, and cytokines, which can act (alone or in concert) to
adversely affect the structure and function of the heart. These
neurohormonal factors not only increase the hemodynamic
stresses on the ventricle by causing sodium retention and
peripheral vasoconstriction but may also exert direct toxic
effects on cardiac cells and stimulate myocardial fibrosis, which
can further alter the architecture and impair the performance of
the failing heart. Neurohormonal activation also has direct
deleterious effects on the myocytes and interstitium, altering the
performance and phenotype of these cells.
The development of HF can be appropriately characterized
by considering 4 stages of the disease, as described in the
Introduction. This staging system recognizes that HF, like
coronary artery disease, has established risk factors and
structural prerequisites; that the development of HF has
asymptomatic and symptomatic phases; and that specific
treatments targeted at each stage can reduce the morbidity
and mortality of HF (Figure 1).
Stages in the development of HF/recommended therapy by
stage. FHx CM indicates family history of cardiomyopathy;
ACEI, angiotensin converting enzyme inhibitors; and ARB,
angiotensin receptor blocker.
III. Initial and Serial Clinical Assessment of
Patients Presenting With HF
In this section, recommendations for the evaluation of pa-
tients with HF have been separated into 2 sets of recommen-
dations: 1) for the initial clinical assessment of patients
presenting with HF and 2) for the serial clinical assessment of
patients presenting with HF.
RECOMMENDATIONS FOR THE INITIAL CLINICAL ASSESSMENT OF
PATIENTS PRESENTING WITH HEART FAILURE
CLASS I
1. A thorough history and physical examination should be
obtained/performed in patients presenting with HF to
identify cardiac and noncardiac disorders or behaviors
that might cause or accelerate the development or progres-
sion of HF. (Level of Evidence: C)
2. A careful history of current and past use of alcohol,
illicit drugs, current or past standard or “alternative
therapies,” and chemotherapy drugs should be ob-
tained from patients presenting with HF. (Level of
Evidence: C)
3. In patients presenting with HF, initial assessment should be
made of the patient’s ability to perform routine and desired
activities of daily living. (Level of Evidence: C)
4. Initial examination of patients presenting with HF should
include assessment of the patient’s volume status, ortho-
static blood pressure changes, measurement of weight
and height, and calculation of body mass index. (Level
of Evidence: C)
5. Initial laboratory evaluation of patients presenting with HF
should include complete blood count, urinalysis, serum
electrolytes (including calcium and magnesium), blood
urea nitrogen, serum creatinine, fasting blood glucose
(glycohemoglobin), lipid profile, liver function tests, and
thyroid-stimulating hormone. (Level of Evidence: C)
1120 Hunt et al. JACC Vol. 46, No. 6, 2005
ACC/AHA 2005 Chronic Heart Failure Guideline Update September 20, 2005:1116–43
6. Twelve-lead electrocardiogram and chest radiograph (PA
and lateral) should be performed initially in all patients
presenting with HF. (Level of Evidence: C)
7. Two-dimensional echocardiography with Doppler should
be performed during initial evaluation of patients pres-
enting with HF to assess LVEF, LV size, wall thickness,
and valve function. Radionuclide ventriculography can be
performed to assess LVEF and volumes. (Level of Evi-
dence: C)
8. Coronary arteriography should be performed in patients
presenting with HF who have angina or significant ische-
mia unless the patient is not eligible for revasculariza-
tion of any kind. (Level of Evidence: B)
CLASS IIA
1. Coronary arteriography is reasonable for patients pres-
enting with HF who have chest pain that may or may not
be of cardiac origin who have not had evaluation of their
coronary anatomy and who have no contraindications to
coronary revascularization. (Level of Evidence: C)
2. Coronary arteriography is reasonable for patients pres-
enting with HF who have known or suspected coronary
artery disease but who do not have angina unless the
patient is not eligible for revascularization of any kind.
(Level of Evidence: C)
3. Noninvasive imaging to detect myocardial ischemia and
viability is reasonable in patients presenting with HF who
have known coronary artery disease and no angina unless
the patient is not eligible for revascularization of any
kind. (Level of Evidence: B)
4. Maximal exercise testing with or without measurement
of respiratory gas exchange and/or blood oxygen satu-
ration is reasonable in patients presenting with HF to
help determine whether HF is the cause of exercise
limitation when the contribution of HF is uncertain.
(Level of Evidence: C)
5. Maximal exercise testing with measurement of respiratory
gas exchange is reasonable to identify high-risk patients
presenting with HF who are candidates for cardiac trans-
plantation or other advanced treatments. (Level of Evi-
dence: B)
6. Screening for hemochromatosis, sleep-disturbed breath-
ing, or human immunodeficiency virus is reasonable in
selected patients who present with HF. (Level of Evidence:
C)
7. Diagnostic tests for rheumatologic diseases, amyloid-
osis, or pheochromocytoma are reasonable in patients
presenting with HF in whom there is a clinical suspicion
of these diseases. (Level of Evidence: C)
8. Endomyocardial biopsy can be useful in patients
presenting with HF when a specific diagnosis is
Figure 1. Stages in the development of HF/recommended therapy by stage. FHx CM indicates family history of cardiomyopathy; ACEI,
angiotensin converting enzyme inhibitors; and ARB, angiotensin receptor blocker.
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suspected that would influence therapy. (Level of
Evidence: C)
9. Measurement of B-type natriuretic peptide (BNP)* can
be useful in the evaluation of patients presenting in the
urgent care setting in whom the clinical diagnosis of HF
is uncertain. (Level of Evidence: A)
CLASS IIB
1. Noninvasive imaging may be considered to define the
likelihood of coronary artery disease in patients with HF
and LV dysfunction. (Level of Evidence: C)
2. Holter monitoring might be considered in patients
presenting with HF who have a history of MI and are
being considered for electrophysiologic study to docu-
ment VT inducibility. (Level of Evidence: C)
CLASS III
1. Endomyocardial biopsy should not be performed in the
routine evaluation of patients with HF. (Level of Evidence:
C)
2. Routine use of signal-averaged electrocardiography is not
recommended for the evaluation of patients presenting
with HF. (Level of Evidence: C)
3. Routine measurement of circulating levels of neurohor-
mones (e.g., norepinephrine or endothelin) is not recom-
mended for patients presenting with HF. (Level of Evi-
dence: C)
RECOMMENDATIONS FOR SERIAL CLINICAL ASSESSMENT OF
PATIENTS PRESENTING WITH HF
CLASS I
1. Assessment should be made at each visit of the ability of
a patient with HF to perform routine and desired
activities of daily living. (Level of Evidence: C)
2. Assessment should be made at each visit of the volume
status and weight of a patient with HF. (Level of
Evidence: C)
3. Careful history of current use of alcohol, tobacco, illicit
drugs, “alternative therapies,” and chemotherapy
drugs, as well as diet and sodium intake, should be
obtained at each visit of a patient with HF. (Level of
Evidence: C)
CLASS IIA
1. Repeat measurement of EF and the severity of struc-
tural remodeling can provide useful information in
patients with HF who have had a change in clinical
status or who have experienced or recovered from a
clinical event or received treatment that might have
had a significant effect on cardiac function. (Level of
Evidence: C)
CLASS IIB
1. The value of serial measurements of BNP to guide
therapy for patients with HF is not well established.
(Level of Evidence: C)
A. Initial Evaluation of Patients
1. Identification of a Structural and
Functional Abnormality
The single most useful diagnostic test in the evaluation of
patients with HF is the comprehensive 2-dimensional echo-
cardiogram coupled with Doppler flow studies to determine
whether abnormalities of myocardium, heart valves, or peri-
cardium are present and which chambers are involved. A
comprehensive echocardiographic evaluation is important,
because it is common for patients to have more than 1 cardiac
abnormality that contributes to the development of HF.
Furthermore, the study may serve as a baseline for compar-
ison, because measurement of EF and the severity of struc-
tural remodeling can provide useful information in patients
who have had a change in clinical status or who have
experienced or recovered from a clinical event or received
treatment that might have had a significant effect on cardiac
function. Other tests such as radionuclide ventriculography or
magnetic resonance imaging may also be used to provide
information regarding the nature and severity of the cardiac
abnormality.
2. Evaluation of the Cause of HF
a. History and Physical Examination
Evaluation of potential causative factors begins with a thor-
ough history and careful physical examination (Table 1).
b. Laboratory Testing
Laboratory testing may reveal the presence of disorders or
conditions that can lead to or exacerbate HF. The initial
evaluation of patients with HF should include a complete
blood count, urinalysis, serum electrolytes (including calcium
and magnesium), glycohemoglobin, and blood lipids, as well
as tests of both renal and hepatic function, a chest radiograph,
and a 12-lead electrocardiogram. Thyroid-function tests (es-
pecially thyroid-stimulating hormone) should be measured,
because both hyperthyroidism and hypothyroidism can be a
primary or contributory cause of HF.
Several recent assays have been developed for BNP and
related peptides. Several of the natriuretic peptides are syn-
thesized by and released from the heart. Elevated plasma
BNP levels have been associated with reduced LVEF (13),
LVH, elevated LV filling pressures, and acute MI and
ischemia, although they can occur in other settings, such as
pulmonary embolism and chronic obstructive pulmonary
disease. They are sensitive to other biological factors, such as
age, sex, weight, and renal function (14). Elevated levels lend
support to a diagnosis of abnormal ventricular function or
hemodynamics causing symptomatic HF (15). Trials with this
diagnostic marker suggest utility in the urgent-care setting,
where it has been used in combination with clinical evalua-
tion to differentiate dyspnea due to HF from dyspnea of other
causes (13,16), and suggest that its use may reduce the time
to hospital discharge and the cost of treatment (17). B-type
natriuretic peptide levels tend to be less elevated in HF with
preserved EF than in HF with low EF and are lower in obese
patients (18,19). Levels of BNP may be meaningfully ele-
vated in women and in people over 60 years of age who do
not have HF, and thus BNP levels should be interpreted
*Note in proof: The writing committee intended BNP to indicate B-type natriuretic
peptide rather than a specific type of assay. Assessment can be made using assays for
BNP or N-terminal proBNP. The two types of assays yield clinically similar information.
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cautiously in such individuals when distinguishing between
cardiac and noncardiac causes of dyspnea (13). Elevated BNP
levels may lend weight to a suspected diagnosis of HF or
trigger consideration of HF when the diagnosis is unknown
but should not be used in isolation to confirm or exclude the
presence of HF (17,20).
B. Ongoing Evaluation of Patients
1. Assessment of Volume Status
It is critically important for healthcare providers to evaluate
the fluid or volume status of patients with HF during the
initial visit and each follow-up examination. This assessment
plays a pivotal role in determining the need for diuretic
therapy and in detecting sodium excesses or deficiencies that
may limit efficacy and decrease the tolerability of drugs used
to treat HF. The physical examination is the primary step in
evaluating the presence and severity of fluid retention in
patients with HF. At each visit, healthcare providers should
record the patient’s body weight and sitting and standing
blood pressures and determine the degree of jugular venous
distension and its response to abdominal pressure, the pres-
ence and severity of organ congestion (pulmonary rales and
hepatomegaly), and the magnitude of peripheral edema in the
legs, abdomen, presacral area, and scrotum, as well as ascites
in the abdomen.
2. Laboratory Assessment
Serum electrolytes and renal function should be monitored
routinely in patients with HF. Of particular importance is the
serial measurement of serum potassium concentration, because
hypokalemia is a common adverse effect of treatment with
diuretics and may cause fatal arrhythmias and increase the risk
of digitalis toxicity, whereas hyperkalemia may complicate
therapy with angiotensin converting enzyme (ACE) inhibitors
(ACEIs), angiotensin II receptor blockers (ARBs), and aldoste-
rone antagonists. Worsening renal function may require adjust-
ment of the doses of diuretics, renin-angiotensin-aldosterone
system antagonists, digoxin, and noncardiac medications. De-
velopment of hyponatremia or anemia may be a sign of disease
progression and is associated with impaired survival.
Serum BNP levels have been shown to parallel the clinical
severity of HF as assessed by NYHA class in broad populations.
Levels are higher in hospitalized patients and tend to decrease
during aggressive therapy for decompensation (see Section
3.1.3.2 on BNP in the full-text guidelines) (15). However, it
cannot be assumed that BNP levels can be used effectively as
targets for adjustment of therapy in individual patients. Ongoing
trials will help to determine the role of serial BNP measurements
in both diagnosis and management of HF.
Repeat assessment of EF may be most useful when the
patient has demonstrated a major change in clinical status.
Both improvement and deterioration may have important
implications for future care, although the recommended
medical regimen should be continued in most cases. Improve-
ment may reflect recovery from a previous condition, such as
viral myocarditis or hypothyroidism, or may occur after
titration of recommended therapies for chronic HF. Deterio-
ration may reflect gradual disease progression or a new event,
such as recurrent MI. Routine assessment of EF at frequent,
regular, or arbitrary intervals is not recommended.
3. Assessment of Prognosis
Although both healthcare providers and patients may be inter-
ested in defining the prognosis of an individual patient with HF,
the likelihood of survival can be determined reliably only in
populations and not in individuals. However, some attempt at
prognostication in HF may provide better information for pa-
tients and their families to appropriately plan for their futures. It
also identifies patients in whom cardiac transplantation or
mechanical device therapy should be considered.
IV. Therapy
Table 2 describes cardiovascular medications useful for
treatment of various stages of HF (see the Figure for an
explanation of the stages of HF).
A. Patients at High Risk for Developing HF (Stage A)
RECOMMENDATIONS
CLASS I
1. In patients at high risk for developing HF, systolic and
diastolic hypertension should be controlled in accordance
with contemporary guidelines. (Level of Evidence: A)
2. In patients at high risk for developing HF, lipid disorders
should be treated in accordance with contemporary guide-
lines. (Level of Evidence: A)
TABLE 1. Evaluation of the Cause of Heart Failure: The History









History or symptoms of sleep-disordered breathing
Exposure to cardiotoxic agents
Current and past alcohol consumption
Smoking
Collagen vascular disease




Family history to include inquiry regarding:
Predisposition to atherosclerotic disease (Hx of MIs, strokes, PAD)
Sudden cardiac death
Myopathy




HF indicates heart failure; Hx, history; MI, myocardial infarction; and PAD,
peripheral arterial disease.
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3. For patients with diabetes mellitus (who are all at high
risk for developing HF), blood sugar should be con-
trolled in accordance with contemporary guidelines.
(Level of Evidence: C)
4. Patients at high risk for developing HF should be coun-
seled to avoid behaviors that may increase the risk of HF
(e.g., smoking, excessive alcohol consumption, and illicit
drug use). (Level of Evidence: C)
5. Ventricular rate should be controlled or sinus rhythm
restored in patients with supraventricular
tachyarrhythmias who are at high risk for developing HF.
(Level of Evidence: B)
6. Thyroid disorders should be treated in accordance with
contemporary guidelines in patients at high risk for
developing HF. (Level of Evidence: C)
7. Healthcare providers should perform periodic evaluation
for signs and symptoms of HF in patients at high risk for
developing HF. (Level of Evidence: C)
8. In patients at high risk for developing HF who have
known atherosclerotic vascular disease, healthcare pro-
viders should follow current guidelines for secondary
prevention. (Level of Evidence: C)
9. Healthcare providers should perform a noninvasive eval-
uation of LV function (i.e., LVEF) in patients with a
strong family history of cardiomyopathy or in those
receiving cardiotoxic interventions. (Level of Evidence: C)
CLASS IIA
1. Angiotensin converting enzyme inhibitors can be useful
to prevent HF in patients at high risk for developing HF
who have a history of atherosclerotic vascular disease,
diabetes mellitus, or hypertension with associated car-
diovascular risk factors. (Level of Evidence: A)
2. Angiotensin II receptor blockers can be useful to pre-
vent HF in patients at high risk for developing HF who
have a history of atherosclerotic vascular disease, dia-
betes mellitus, or hypertension with associated cardio-
vascular risk factors. (Level of Evidence: C)
CLASS III
1. Routine use of nutritional supplements solely to prevent the
development of structural heart disease should not be
recommended for patients at high risk for developing HF.
(Level of Evidence: C)
1. Control of Risk
a. Treatment of Hypertension
Elevated levels of diastolic and especially systolic blood
pressure are major risk factors for the development of HF
(21,22), and long-term treatment of both systolic and diastolic
hypertension has been shown to reduce the risk of HF
(23–25). A number of large, controlled studies have quite
uniformly demonstrated that optimal blood pressure control
decreases the risk of new HF by approximately 50% (26).
Healthcare providers should lower both systolic and dia-
stolic blood pressure in accordance with the recommenda-
tions provided in published guidelines, including the most
recently published report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (27); target levels of blood pressure are lower
in patients with associated major cardiovascular risk factors,
especially those with diabetes mellitus (27a,27b). When an
antihypertensive regimen is devised, optimal control of blood
pressure should remain as the primary goal, with the choice of
drugs determined by the concomitant medical problems (e.g.,
coronary artery disease, diabetes, or renal disease). Diuretic-
based antihypertensive therapy has repeatedly been shown to
TABLE 2. Cardiovascular Medications Useful for Treatment of
Various Stages* of Heart Failure
Drug Stage A Stage B Stage C
ACE inhibitors
Benazepril H      
Captopril H, DN Post MI HF
Enalapril H, DN Asymptomatic LVSD HF
Fosinopril H    HF
Lisinopril H, DN Post MI HF
Moexipril H      
Perindopril H, CV Risk      
Quinapril H    HF
Ramipril H, CV Risk Post MI Post MI
Trandolapril H Post MI Post MI
Angiotensin receptor blockers
Candesartan H    HF
Eprosartan H      
Irbesartan H, DN      
Losartan H, DN CV Risk   
Olmesartan H      
Telmisartan H      
Valsartan H, DN Post MI Post MI, HF
Adosterone blockers
Eplerenone H Post MI Post MI
Spironolactone H    HF
Beta-blockers
Acebutolol H      
Atenolol H Post MI   
Betaxolol H      
Bisoprolol H    HF
Carteolol H      
Carvedilol H Post MI HF, Post MI
Labetalol H      
Metoprolol succinate H    HF
Metoprolol tartrate H Post MI   
Nadolol H      
Penbutolol H      
Pindolol H      
Propranolol H Post MI   
Timolol H Post MI   
Digoxin       HF
*See Figure for explanation of stages of heart failure.
Asymptomatic LVSD indicates Asymptomatic left ventricular systolic dys-
function; CV Risk, reduction in future cardiovascular events; DN, diabetic
nephropathy; H, hypertension; HF, heart failure and asymptomatic left ventric-
ular dysfunction; Post MI, reduction in heart failure or other cardiac events
following myocardial infarction.
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prevent HF in a wide range of target populations (30).
Angiotensin converting enzyme inhibitors and beta-blockers
are also effective in the prevention of HF (27), whereas
calcium antagonists and alpha-blockers are less effective in
preventing HF syndrome (31). However, ACEIs and beta-
blockers, as single therapies, are not superior to other anti-
hypertensive drug classes in the reduction of all cardiovas-
cular outcomes. Nevertheless, among patients with diabetes
or other cardiovascular complications (32,33), ACEIs have
been most notable with respect to a reduction in the onset of
HF and new-onset diabetes. Likewise, compared with pla-
cebo, the ARBs losartan (34) and irbesartan (35) significantly
reduced the incidence of HF in patients with type 2 diabetes
mellitus and nephropathy. Ultimately, an appropriate antihy-
pertensive regimen frequently consists of several drugs used
in combination. Although prevention of HF is the focus of
these guidelines, overall cardiovascular preventative strate-
gies have also been the subject of published guidelines (36).
b. Treatment of Diabetes
Obesity and insulin resistance are important risk factors for
the development of HF (28,37). The presence of clinical diabetes
mellitus markedly increases the likelihood of HF in patients
without structural heart disease (29) and adversely affects the
outcomes of patients with established HF (38,39). In a study of
patients with type 2 diabetes mellitus more than 50 years of age
who had urinary albumin greater than 20 mg per liter, 4% of
patients developed HF over the study period, of whom 36% died
(40). The occurrence of HF represents a major and adverse
prognostic turn in a diabetic patient’s life. There is a differential
gender effect associated with this risk; diabetes mellitus only
modestly increases the risk of HF for men, but it increases the
relative risk of HF more than 3-fold among women (21).
Healthcare providers should make every effort to control hyper-
glycemia, although such control has not yet been shown to
reduce the subsequent risk of HF. In addition, ACEIs or ARBs
can prevent the development of end-organ disease and the
occurrence of clinical events in diabetic patients, even in those
who do not have hypertension (32,41). Long-term treatment
with several ACEIs or ARBs has been shown to decrease the
risk of renal disease in diabetic patients (42,42a), and prolonged
therapy with the ACEI ramipril has been shown to lower the
likelihood of cardiovascular death, MI, and HF (32). Likewise,
the use of ARBs in patients with diabetes mellitus and hyper-
tension or LVH has been shown to reduce the incidence of first
hospitalization for HF, in addition to having other beneficial
effects on renal function (34,35,43).
c. Management of the Metabolic Syndrome
The clustering of cardiovascular risk factors in individual
patients, termed the metabolic syndrome or syndrome X,
includes any 3 of the criteria of abdominal adiposity, hyper-
triglyceridemia, low high-density lipoprotein, hypertension,
and fasting hyperglycemia. It is estimated that the prevalence
of the metabolic syndrome in the United States exceeds 20%
of individuals who are at least 20 years of age, and 40% of the
population over 40 years of age (44). A number of trials are
currently in progress to determine the most effective inter-
vention for patients with the metabolic syndrome.
d. Management of Atherosclerotic Disease
Patients with known atherosclerotic disease (e.g., of the
coronary, cerebral, or peripheral blood vessels) are likely to
develop HF, and healthcare providers should seek to control
vascular risk factors in such patients according to recommended
guidelines (36). In one large-scale trial, long-term treatment with
an ACEI decreased the risk of the primary end point of
cardiovascular death, MI, and stroke in patients with established
vascular disease who were without evidence of HF or reduced
LVEF at the time of randomization, but the incidence of new HF
was not a primary or secondary end point although it was
improved (32). Among patients with established coronary artery
disease and no HF, another ACEI significantly reduced the
incidence of death, MI or cardiac arrest (33). A more recent large
trial of ACEI versus placebo failed to show a reduction in the
primary composite end point, although a post hoc analysis did
show some reduction in HF hospitalization (44a). The commit-
tee, in reviewing the accruing data, decided to change the level
of recommendation for the use of ACEI for Stage A patients
from Class I in the 2001 document to Class IIa in this document.
Treatment of hyperlipidemia (in accordance with published
guidelines) has been shown to reduce the likelihood of death and
of HF in patients with a history of MI (45,45a,45b,45c).
e. Control of Conditions That May Cause Cardiac Injury
Many therapeutic and recreational agents can exert impor-
tant cardiotoxic effects, and patients should be strongly
advised about the hazards of smoking, as well as the use of
alcohol, cocaine, amphetamines, and other illicit drugs. Sev-
eral epidemiological studies have revealed no correlation
between the amount of alcohol ingested and the subsequent
development of HF; nevertheless, the Writing Committee
strongly believed that any patient with a history of alcohol
abuse or with current substantial routine alcohol consumption
and new-onset HF without other obvious cause should be
counseled to become abstinent. Many HF programs limit
alcoholic beverage consumption to no more than 1 alcoholic
beverage serving daily for all patients with LV dysfunction,
regardless of cause (46,47). Use of ephedra, formerly a
common ingredient in over-the-counter weight loss prepara-
tions, may contribute to the development of HF as well (48).
f. Other Measures
There is no direct evidence that control of dietary sodium
or participation in regular exercise can prevent the develop-
ment of HF. However, in patients with hypertension or other
vascular disease, these efforts may have other health benefits
and may enhance a general sense of well-being.
2. Early Detection of Structural Abnormalities
Asymptomatic patients with ventricular dilatation and
reduced LVEF carry substantially higher risk for subse-
quent morbidity and mortality than the general population.
It would be desirable to construct cost-effective strategies
to identify such patients in the interest of reducing their
subsequent risk. Limited information is available to sup-
port the cost-effectiveness of broad population screening.
Brain natriuretic peptide levels represent a potential tool
for this purpose (49). An analysis of the implications of
elevated BNP has suggested that the screening of asymp-
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tomatic people over the age of 60 years with this blood test
could yield cost-effective improvement in clinical out-
comes across the population (50).
B. Patients With Cardiac Structural Abnormalities




1. All Class I recommendations for Stage A should apply to patients
with cardiac structural abnormalities who have not developed
HF. (Levels of Evidence: A, B, and C as appropriate)
2. Beta-blockers and ACEIs should be used in all patients
with a recent or remote history of MI regardless of EF or
presence of HF (see Table 2). (Level of Evidence: A)
3. Beta-blockers are indicated in all patients without a
history of MI who have a reduced LVEF with no HF
symptoms (see Table 2 and text). (Level of Evidence: C)
4. Angiotensin converting enzyme inhibitors should be used in
patients with a reduced EF and no symptoms of HF, even if
they have not experienced MI. (Level of Evidence: A)
5. An ARB should be administered to post-MI patients
without HF who are intolerant of ACE inhibitors and
have a low LVEF. (Level of Evidence: B)
6. Patients who have not developed HF symptoms should
be treated according to contemporary guidelines after
an acute MI. (Level of Evidence: C)
7. Coronary revascularization should be recommended in
appropriate patients without symptoms of HF in accor-
dance with contemporary guidelines (see ACC/AHA
Guidelines for the Management of Patients With
Chronic Stable Angina). (Level of Evidence: A)
8. Valve replacement or repair should be recommended for
patients with hemodynamically significant valvular steno-
sis or regurgitation and no symptoms of HF in accordance
with contemporary guidelines. (Level of Evidence: B)
CLASS IIA
1. Angiotensin converting enzyme inhibitors or ARBs can
be beneficial in patients with hypertension and LVH
and no symptoms of HF. (Level of Evidence B)
2. Angiotensin II receptor blockers can be beneficial in
patients with low EF and no symptoms of HF who are
intolerant of ACEIs. (Level of Evidence: C)
3. Placement of an ICD is reasonable in patients with
ischemic cardiomyopathy who are at least 40 days
post-MI, have an LVEF of 30% or less, are NYHA
functional class I on chronic optimal medical therapy,
and have reasonable expectation of survival with a good
functional status for more than 1 year. (Level of Evi-
dence: B)
CLASS IIB
1. Placement of an implantable cardioverter-
defibrillator might be considered in patients without
HF who have nonischemic cardiomyopathy and an
LVEF less than or equal to 30% who are in NYHA
functional Class I with chronic optimal medical
therapy and have a reasonable expectation of sur-
vival with good functional status for more than 1
year. (Level of Evidence: C)
CLASS III
1. Digoxin should not be used in patients with low EF, sinus
rhythm, and no history of HF symptoms, because in this
population, the risk of harm is not balanced by any
known benefit. (Level of Evidence: C)
2. Use of nutritional supplements to treat structural heart
disease or to prevent the development of symptoms of HF
is not recommended. (Level of Evidence: C)
3. Calcium channel blockers with negative inotropic ef-
fects may be harmful in asymptomatic patients with
low LVEF and no symptoms of HF after MI (see text in
Stage C). (Level of Evidence: C)
1. Prevention of Cardiovascular Events
a. Patients With an Acute MI
For recommendations on the treatment of patients with MI,
see the ACC/AHA Guidelines for the Management of Pa-
tients With ST-Elevation Myocardial Infarction (9).
b. Patients With Chronic Reduction of LVEF but No
Symptoms
Long-term treatment with an ACEI has been shown to
delay the onset of HF symptoms and decrease the combined
risk of death and hospitalization for HF in asymptomatic
patients with reduced LVEF, whether due to a remote
ischemic injury or to a nonischemic cardiomyopathy (51,52).
Although a recent trial investigated patients with low EF and
HF at the time of MI, there are no studies that specifically
address use of ARBs in asymptomatic patients with reduced
LVEF. Given the results of studies in symptomatic patients
with low EF, ARBs may be an appropriate alternative,
particularly in patients who cannot tolerate an ACEI. Further-
more, although controlled clinical trials are lacking, the use of
beta-blockers in patients with a low EF and no symptoms
(especially those with coronary artery disease) is also recom-
mended (53,54). In such cases, the same beta-blockers should
be used that were employed in the large HF trials.
The use of ICD therapy in patients with chronic reduction
of LVEF but no symptoms has been evaluated in one large
trial including only patients with ischemic cardiomyopathy.
The trials assessing ICD for primary prophylaxis in non-
ischemic cardiomyopathy have not included functional class
I patients, and the efficacy of ICDs in this population as a
whole is unknown (54a). The trial involving patients with
ischemic cardiomyopathy included a subset of asymptomatic
patients post-MI with LVEF 30% or less, and there was
demonstrated benefit of ICD placement (MADIT-II) in that
subset. The findings potentially apply to large numbers of
patients, and the number needed to treat to have benefit would
be great. The writing committee struggled with this issue
because guidelines are meant to summarize current science
and not take into account economic issues or the societal
impact of making a recommendation. However, the commit-
tee recognizes that economic impact and societal issues will
clearly modulate how these recommendations are imple-
mented.
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In contrast, there are no data to recommend the use of
digoxin in patients with asymptomatic reduction of LVEF,
except in those with atrial fibrillation. Likewise, there are no
data to recommend the routine use of calcium channel
blockers in patients with asymptomatic reduction of LVEF,
but they have not been shown to have adverse effects and may
be helpful for concomitant conditions such as hypertension.
However, the use of calcium channel blockers with negative
inotropic effects is not recommended in asymptomatic pa-
tients with EF less than 40% after MI (55).
C. Patients With Current or Prior Symptoms of
HF (Stage C)
1. Patients With Reduced LVEF
RECOMMENDATIONS
CLASS I
1. Measures listed as Class I recommendations for patients
in stages A and B are also appropriate for patients in Stage
C. (Levels of Evidence: A, B, and C as appropriate)
2. Diuretics and salt restriction are indicated in patients
with current or prior symptoms of HF and reduced
LVEF who have evidence of fluid retention (see Table
3). (Level of Evidence: C)
3. Angiotensin converting enzyme inhibitors are recom-
mended for all patients with current or prior symptoms
of HF and reduced LVEF, unless contraindicated (see
Table 2 and text). (Level of Evidence: A)
4. Beta-blockers (using 1 of the 3 proven to reduce
mortality, ie. bisoprolol, carvedilol, and sustained
release metoprolol succinate) are recommended for
all stable patients with current or prior symptoms of HF
and reduced LVEF, unless contraindicated (see Table 2
and text). (Level of Evidence: A)
5. Angiotensin II receptor blockers approved for the
treatment of HF (see Table 2) are recommended in
patients with current or prior symptoms of HF and
reduced LVEF who are ACEI intolerant (see text
for information regarding patients with angio-
edema). (Level of Evidence: A)
6. Drugs known to adversely affect the clinical status of
patients with current or prior symptoms of HF and
reduced LVEF should be avoided or withdrawn when-
ever possible (e.g., nonsteroidal anti-inflammatory drugs,
most antiarrhythmic drugs, and most calcium channel
blocking drugs; see text). (Level of Evidence: B)
7. Exercise training is beneficial as an adjunctive
approach to improve clinical status in ambulatory
patients with current or prior symptoms of HF and
reduced LVEF. (Level of Evidence: B)
8. An implantable cardioverter-defibrillator is recom-
mended as secondary prevention to prolong sur-
vival in patients with current or prior symptoms of
HF and reduced LVEF who have a history of
cardiac arrest, ventricular fibrillation, or hemody-
namically destabilizing ventricular tachycardia.
(Level of Evidence: A)
9. Implantable cardioverter-defibrillator therapy is
recommended for primary prevention to reduce
total mortality by a reduction in sudden cardiac
death in patients with ischemic heart disease who
are at least 40 days post-MI, have an LVEF less
than or equal to 30%, with NYHA functional class
TABLE 3. Oral Diuretics Recommended for Use in the Treatment of Fluid Retention in Chronic
Heart Failure






Bumetanide 0.5 to 1.0 mg once or twice 10 mg 4 to 6 hours
Furosemide 20 to 40 mg once or twice 600 mg 6 to 8 hours
Torsemide 10 to 20 mg once 200 mg 12 to 16 hours
Thiazide diuretics
Chlorothiazide 250 to 500 mg once or twice 1000 mg 6 to 12 hours
Chlorthalidone 12.5 to 25 mg once 100 mg 24 to 72 hours
Hydrochlorothiazide 25 mg once or twice 200 mg 6 to 12 hours
Indapamide 2.5 once 5 mg 36 hours
Metolazone 2.5 mg once 20 mg 12 to 24 hours
Potassium-sparing diuretics
Amiloride 5 mg once 20 mg 24 hours
Spironolactone 12.5 to 25 mg once 50 mg* 2 to 3 days
Triamterene 50 to 75 mg twice 200 mg 7 to 9 hours
Sequential nephron blockade
Metolazone 2.5 to 10 mg once plus loop diuretic
Hydrochlorothiazide 25 to 100 mg once or twice plus loop diuretic
Chlorothiazide (IV) 500 to 1000 mg once plus loop diuretic
mg indicates milligrams.
*Higher doses may occasionally be used with close monitoring.
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II or III symptoms while undergoing chronic opti-
mal medical therapy, and have reasonable expecta-
tion of survival with a good functional status for
more than 1 year. (Level of Evidence: A)
10. Implantable cardioverter-defibrillator therapy is
recommended for primary prevention to reduce
total mortality by a reduction in sudden cardiac
death in patients with nonischemic cardiomyopathy
who have an LVEF less than or equal to 30%, with
NYHA functional class II or III symptoms while
undergoing chronic optimal medical therapy, and
have reasonable expectation of survival with a good
functional status for more than 1 year. (Level of
Evidence: B)
11. Patients with LVEF less than or equal to 35%, sinus
rhythm, and NYHA functional class III or ambula-
tory class IV symptoms despite recommended, op-
timal medical therapy and who have cardiac dys-
synchrony, which is currently defined as a QRS
duration greater than 0.12 ms, should receive car-
diac resynchronization therapy unless contraindi-
cated. (Level of Evidence: A)
12. Addition of an aldosterone antagonist is reasonable
in selected patients with moderately severe to severe
symptoms of HF and reduced LVEF who can be
carefully monitored for preserved renal function
and normal potassium concentration. Creatinine
should be less than or equal to 2.5 mg/dL in men or
less than or equal to 2.0 mg/dL in women and
potassium should be less than 5.0 mEq/l. (Under
circumstances where monitoring for hyperkalemia
or renal dysfunction is not anticipated to be feasible,
the risks may outweigh the benefits of aldosterone
antagonists.) (Level of Evidence: B)
CLASS IIA
1. Angiotensin II receptor blockers are reasonable to use
as alternatives to ACEIs as first-line therapy for pa-
tients with mild to moderate HF and reduced LVEF,
especially for patients already taking ARBs for other
indications. (Level of Evidence: A)
2. Digitalis can be beneficial in patients with current or
prior symptoms of HF and reduced LVEF to decrease
hospitalizations for HF. (Level of Evidence: B)
3. The addition of a combination of hydralazine and a nitrate
is reasonable for patients with reduced LVEF who are
already taking an ACEI and beta-blocker for symptomatic
HF and who have persistent symptoms. (Level of Evi-
dence: A)
4. Placement of an implantable cardioverter-defibrillator
is reasonable in patients with LVEF of 30% to 35% of
any origin with NYHA functional class II or III symp-
toms who are taking chronic optimal medical therapy
and who have reasonable expectation of survival with
good functional status of more than 1 year. (Level of
Evidence: B)
CLASS IIB
1. A combination of hydralazine and a nitrate might be
reasonable in patients with current or prior symptoms
of HF and reduced LVEF who cannot be given an
ACEI or ARB because of drug intolerance, hypoten-
sion, or renal insufficiency. (Level of Evidence: C)
2. The addition of an ARB may be considered in persis-
tently symptomatic patients with reduced LVEF who
are already being treated with conventional therapy.
(Level of Evidence: B)
CLASS III
1. Routine combined use of an ACEI, ARB, and aldoste-
rone antagonist is not recommended for patients with
current or prior symptoms of HF and reduced LVEF.
(Level of Evidence: C)
2. Calcium channel blocking drugs are not indicated as
routine treatment for HF in patients with current or
prior symptoms of HF and reduced LVEF. (Level of
Evidence: A)
3. Long-term use of an infusion of a positive inotropic drug
may be harmful and is not recommended for patients with
current or prior symptoms of HF and reduced LVEF,
except as palliation for patients with end-stage disease
who cannot be stabilized with standard medical treat-
ment (see recommendations for Stage D). (Level of
Evidence: C)
4. Use of nutritional supplements as treatment for HF is not
indicated in patients with current or prior symptoms of HF
and reduced LVEF. (Level of Evidence: C)
5. Hormonal therapies other than to replete deficiencies
are not recommended and may be harmful to patients
with current or prior symptoms of HF and reduced
LVEF. (Level of Evidence: C)
a. General Measures
Additions were made to the 3 classes of drugs that can
exacerbate the syndrome of HF and that should be avoided in
most patients:
1. Antiarrhythmic agents: Only amiodarone and dofetilide
have been shown not to adversely affect survival (56).
2. Calcium channel blockers: Only the vasoselective ones
have been shown not to adversely affect survival (57,58).
3. Nonsteroidal anti-inflammatory drugs: A discussion of the
use of aspirin as a unique agent is found later in this
section.
Patients with HF should be monitored carefully for
changes in serum potassium, and every effort should be made
to prevent the occurrence of either hypokalemia or hyperka-
lemia. Many experts believe that serum potassium concentra-
tions should be targeted in the 4.0 to 5.0 mmol per liter range.
b. Drugs Recommended for Routine Use
DIURETICS
Thiazide diuretics may be preferred in hypertensive HF
patients with mild fluid retention because they confer more
persistent antihypertensive effects. Tables 3 and 4 illustrate
oral and intravenous diuretics recommended for use in the
treatment of chronic HF.
INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Inhibition of the renin-angiotensin-aldosterone system can
take place at multiple sites: at the level of the enzyme that
converts angiotensin I to angiotensin II (ACEIs), at the
angiotensin receptor (ARBs), or at the receptor for aldoste-
rone, which is under control of both the renin-angiotensin
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system and other systemic and local influences (aldosterone
antagonists). ACEIs are the best studied class of agents in HF,
with multiple mechanisms of benefit for both HF, coronary
disease, and other atherosclerotic vascular disease, as well as
diabetic nephropathy. During chronic therapy with ACEIs,
the renin-angiotensin system demonstrates partial “escape”
from inhibition with “normalization” of angiotensin levels, in
part owing to alternative local pathways for production of
angiotensin. This leaves the potential for benefit from addi-
tional therapy with ARBs and with the aldosterone
antagonists.
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Analysis of a large collective experience indicates that
ACEIs can alleviate symptoms, improve clinical status, and
enhance the overall sense of well-being of patients with HF
(59 –70). In addition, ACEIs can reduce the risk of death and
the combined risk of death or hospitalization (59,60,70).
These benefits of ACE inhibition were seen in patients with
mild, moderate, or severe symptoms and in patients with or
without coronary artery disease.
PRACTICAL USE OF ACE INHIBITORS: SELECTION OF PATIENTS
Angiotensin converting enzyme inhibitors should be pre-
scribed to all patients with HF due to LV systolic dysfunction
with reduced LVEF unless they have a contraindication to
their use or have been shown to be unable to tolerate
treatment with these drugs. Because of their favorable effects
on survival, treatment with an ACEI should not be delayed
until the patient is found to be resistant to treatment with other
drugs. ACEIs are often preferred over the use of ARBs or
direct-acting vasodilators (70,71) because of the greater
experience and weight of evidence supporting their
effectiveness.
Clinicians should attempt to use doses that have been
shown to reduce the risk of cardiovascular events in clinical
trials. If these target doses of an ACEI cannot be used or are
poorly tolerated, intermediate doses should be used with the
expectation that there are likely to be only small differences
in efficacy between low and high doses. More importantly,
clinicians should not delay the institution of beta-blockers in
patients because of a failure to reach target ACEI doses.
Two retrospective reviews have reported no adverse effects
of concomitant aspirin use with ACEIs on long-term survival
(72,73). Given these retrospective results, many physicians
believe the data justify prescribing aspirin and ACEIs to-
gether when there is an indication for use of aspirin. These
large overviews are subject to varying interpretation. Other
physicians would consider not combining aspirin with an
ACEI because there are no data to indicate that it can reduce
the risk of ischemic events in patients with HF (74,75), or
they might consider the use of an alternative antiplatelet agent
such as clopidogrel, which does not interact with ACEIs and
which may have superior effects in preventing ischemic
events (76). However, clopidogrel does not have an indica-
tion for the primary prevention of ischemic events. There may
be an important interaction between aspirin and ACEIs, but
there is controversy regarding this point, and it requires
further study.
Although ARBs may be considered as alternative therapy
for patients who have developed angioedema while taking an
ACEI, there are a small number of patients who have also
developed angioedema with ARBs and extreme caution is
advised when substituting an ARB in a patient who has had
angioedema associated with ACEI use (77–79,79a).
ANGIOTENSIN II RECEPTOR BLOCKERS
Table 5 lists the inhibitors of the renin-angiotensin-aldo-
sterone system and beta-blockers that are commonly used for
the treatment of patients with HF with low EF.
Experience with ARBs in controlled clinical trials of
patients with HF is considerably less than that with ACEIs.
Nevertheless, in several placebo-controlled studies, long-term
therapy with ARBs produced hemodynamic, neurohormonal,
and clinical effects consistent with those expected after
interference with the renin-angiotensin system (80 – 86).
For patients unable to tolerate ACEIs because of cough or
angioedema, the ARBs valsartan and candesartan (79,87)
have demonstrated benefit by reducing hospitalizations and
mortality. The combination of an ACEI and ARBs may
produce more reduction of LV size than either agent alone
(88). The addition of ARBs to chronic ACEI therapy caused
TABLE 4. Intravenous Diuretic Medications Useful for the Treatment of Severe Heart Failure
Drug Initial Dose Maximum Single Dose
Loop diuretics
Bumetanide 1.0 mg 4 to 8 mg
Furosemide 40 mg 160 to 200 mg
Torsemide 10 mg 100 to 200 mg
Thiazide diuretics
Chlorothiazide 500 mg 1000 mg
Sequential nephron blockade Chlorothiazide 500 to 1000 mg (IV) once or twice plus loop diuretics once—multiple doses per day
Metozalone (as Zaroxolyn or Diulo) 2.5 to 5 mg (p.o.) once or twice daily with loop diuretic
IV infusions
Bumetanide 1-mg IV load then 0.5- to 2-mg-per-hour infusion
Furosemide 40-mg IV load then 10- to 40-mg-per-hour infusion
Torsemide 20-mg IV load then 5- to 20-mg -per-hour infusion
IV indicates intravenous; mg, milligrams.
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a modest decrease in hospitalization in 2 studies, with a trend
to decreased total mortality in one and no impact on mortality
in another (87– 89).
PRACTICAL USE OF ARBS
When used, angiotensin receptor antagonists should be
initiated with the starting doses shown in Table 5. Many of
the considerations with ARB are similar to those with
initiation of an ACEI, as discussed above. Blood pressure
(including postural blood pressure changes), renal function,
and potassium should be reassessed within 1 to 2 weeks after
initiation and followed closely after changes in doses. Pa-
tients with systolic blood pressure below 80 mm Hg, low
serum sodium, diabetes mellitus, and impaired renal function
merit particular surveillance during therapy with inhibitors of
the renin-angiotensin-aldosterone system. Titration is gener-
ally achieved by doubling doses. For stable patients, it is
reasonable to add therapy with beta-blocking agents before
full target doses of either ACEIs or ARBs are reached.
The risks of treatment with ARBs are those attributed to
suppression of angiotensin stimulation, as discussed above
for ACEIs. These risks of hypotension, renal dysfunction, and
hyperkalemia are greater when combined with another inhib-
itor of this axis, such as ACEIs or aldosterone antagonists.
ALDOSTERONE ANTAGONISTS
In a large-scale, long-term trial (90), low doses of spirono-
lactone (starting at 12.5 mg daily) were added to ACEI
therapy for patients with class IV HF symptoms or class III
symptoms and recent hospitalization. The risk of death was
reduced from 46% to 35% (30% relative risk reduction) over
2 years, with 35% reduction in HF hospitalization and an
improvement in functional class. Initial creatinine levels were
below 2.0 mg per dl in the dose-ranging pilot trial and below
2.5 mg per dl in the main trial. Potassium replacements were
stopped at trial entry, and serum potassium and renal function
were followed very closely.
A recent trial investigated the newer aldosterone antagonist
eplerenone in patients with LVEF less than or equal to 40%
and clinical evidence of HF or diabetes mellitus within 14
days of MI. Mortality was decreased from 13.6% to 11.8% at
1 year. Hyperkalemia occurred in 5.5% of patients treated
with eplerenone compared with 3.9% of those given placebo
overall and in up to 10.1% versus 4.6% of patients with
estimated creatinine clearance less than 50 ml per min (94).
RECOMMENDATIONS CONCERNING ALDOSTERONE ANTAGONISTS
The addition of low-dose aldosterone antagonists should be
considered in carefully selected patients with moderately
severe or severe HF symptoms and recent decompensation or
with LV dysfunction early after MI. These recommendations
are based on the strong data demonstrating reduced death and
rehospitalization in 2 clinical trial populations (90,94). To
minimize the risk of life-threatening hyperkalemia in patients
with low LVEF and symptoms of HF, patients should have
initial serum creatinine less than 2.0 mg per dl to 2.5 mg per
dl without recent worsening and serum potassium less than
5.0 mEq per dl without a history of severe hyperkalemia. The
safety of the combination of ACEIs, ARBs, and aldosterone
TABLE 5. Inhibitors of the Renin-Angiotensin-Aldosterone System and Beta-Blockers
Commonly Used for the Treatment of Patients With HF With Low Ejection Fraction
Drug Initial Daily Dose(s) Maximum Dose(s)
ACE inhibitors
Captopril 6.25 mg 3 times 50 mg 3 times
Enalapril 2.5 mg twice 10 to 20 mg twice
Fosinopril 5 to 10 mg once 40 mg once
Lisinopril 2.5 to 5 mg once 20 to 40 mg once
Perindopril 2 mg once 8 to 16 mg once
Quinapril 5 mg twice 20 mg twice
Ramipril 1.25 to 2.5 mg once 10 mg once
Trandolapril 1 mg once 4 mg once
Angiotensin receptor blockers
Candesartan 4 to 8 mg once 32 mg once
Losartan 25 to 50 mg once 50 to 100 mg once
Valsartan 20 to 40 mg twice 160 mg twice
Aldosterone antagonists
Spironolactone 12.5 to 25 mg once 25 mg once or twice
Eplerenone 25 mg once 50 mg once
Beta-blockers
Bisoprolol 1.25 mg once 10 mg once
Carvedilol 3.125 mg twice 25 mg twice (50 mg twice for
patients 85 kg)
Metoprolol succinate extended release
(metoprolol CR/XL)
12.5 to 25 mg once 200 mg once
ACE indicates angiotensin-converting enzyme; kg, kilograms; and mg, milligrams.
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antagonists has not been explored adequately, and this com-
bination cannot be recommended.
PRACTICAL USE OF ALDOSTERONE ANTAGONISTS:
SELECTION OF PATIENTS
Decisions regarding the selection of patients for aldoste-
rone antagonists reflect the balance between potential benefit
to decrease death and hospitalization from HF and potential
risks of life-threatening hyperkalemia. Serum creatinine lev-
els often underestimate renal dysfunction, particularly in the
elderly, in whom estimated creatinine clearance less than 50
ml per min should trigger a reduction of the initial dose of
spironolactone to 12.5 mg daily or of eplerenone to 25 mg
daily, and aldosterone antagonists should not be given when
clearance is less than 30 ml per min (see Table 6). Patients
chronically requiring high doses of diuretics without potas-
sium replacement should be evaluated closely, because po-
tassium handling may be impaired.
The major risk of aldosterone antagonists is hyperkalemia due
to inhibition of potassium excretion. The positive results of a
recent trial led to wider use of spironolactone in HF regimens.
The subsequent incidence of hyperkalemia was reported to be as
high as 24% in 1 series (93), in which half of the subjects with
hyperkalemia had potassium levels in excess of 6 mEq per liter.
Similar results were reported from Norway (92). Although this
far exceeded the 2% incidence in the large trial, it is comparable
to the 13% observed in the preceding pilot trial with a 25-mg
dose and 20% with a 50-mg dose.
The potential impact on the overall HF population is
suggested by a population-based analysis in Ontario, Canada
of over 30,000 patients on ACE inhibitors after a HF
hospitalization. After publication of these trial results in
1999, prescriptions for spironolactone in this geographic area
more than tripled, the rate of hospitalization for hyperkalemia
increased from 2.4 to 11 patients per thousand, and the
associated mortality increased from 0.3 to 2 per thousand
(93).
PRACTICAL USE OF ALDOSTERONE ANTAGONISTS:
INITIATION AND MONITORING
Spironolactone should be initiated at a dose of 12.5 to 25
mg daily, or occasionally on alternate days. Eplerenone
was used after MI in one study (94) at doses of 25 mg per
d, increasing to 50 mg daily. Potassium supplementation is
generally stopped after the initiation of aldosterone antag-
onists, and patients should be counseled to avoid high
potassium– containing foods. However, patients who have
required large amounts of potassium supplementation may
need to continue receiving supplementation, albeit at a
lower dose, particularly when previous episodes of hypo-
kalemia have been associated with ventricular arrhythmias.
On the other hand, potassium supplementation required
during vigorous therapy of fluid overload is often no
longer necessary once the goal is to maintain even fluid
balance. Patients should be cautioned to avoid the addition
of nonsteroidal anti-inflammatory agents and cyclo-oxy-
genase-2 inhibitors, which can lead to worsening renal
function and hyperkalemia. Potassium levels and renal
function should be rechecked within 3 days and again at 1
week after initiation of an aldosterone antagonist. Subse-
quent monitoring should be dictated by the general clinical
stability of renal function and fluid status but should occur at
least monthly for the first 3 months and every 3 months
thereafter. The addition or an increase in dosage of ACEIs or
ARBs should trigger a new cycle of monitoring. In view of the
potential risk for hyperkalemia, the committee recommends that
the routine triple combination of ACEIs, ARBs, and an aldoste-
rone antagonist be avoided.
The development of potassium levels in excess of 5.5 mEq
per liter should generally trigger discontinuation or dose
reduction of the aldosterone antagonist unless patients have
been receiving potassium supplementation, which should
then be stopped. The development of worsening renal func-
tion should lead to careful evaluation of the entire medical
regimen and consideration for stopping the aldosterone an-
tagonist. Patients should be instructed specifically to stop the
aldosterone antagonist during an episode of diarrhea or while
loop diuretic therapy is interrupted.
BETA-ADRENERGIC RECEPTOR BLOCKERS
Beta-blockers act principally to inhibit the adverse effects
of the sympathetic nervous system in patients with HF, and
these effects far outweigh their well-known negative inotro-
pic effects. Three beta-blockers have been shown to be
effective in reducing the risk of death in patients with chronic
HF: bisoprolol (95) and sustained-release metoprolol (succi-
nate) (96), which selectively block beta-1-receptors, and
carvedilol (101,102), which blocks alpha-1, beta-1-, and
beta-2- receptors. Positive findings with these 3 agents,
however, should not be considered indicative of a beta-
TABLE 6. Guidelines for Minimizing the Risk of Hyperkalemia
in Patients Treated With Aldosterone Antagonists
1. Impaired renal function is a risk factor for hyperkalemia during treatment
with aldosterone antagonists. The risk of hyperkalemia increases
progressively when serum creatinine exceeds 1.6 mg per dl.* In elderly
patients or others with low muscle mass in whom serum creatinine does
not accurately reflect glomerular filtration rate, determination that
glomerular filtration rate or creatinine clearance exceeds 30 ml per min
is recommended.
2. Aldosterone antagonists should not be administered to patients with
baseline serum potassium in excess of 5.0 mEq per liter.
3. An initial dose of spironolactone 12.5 mg or eplerenone 25 mg is
recommended, after which the dose may be increased to spironolactone
25 mg or eplerenone 50 mg if appropriate.
4. The risk of hyperkalemia is increased with concomitant use of higher
doses of ACEIs (captopril greater than or equal to 75 mg daily; enalapril
or lisinopril greater than or equal to 10 mg daily).
5. Nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors
should be avoided.
6. Potassium supplements should be discontinued or reduced.
7. Close monitoring of serum potassium is required; potassium levels and
renal function should be checked in 3 days and at 1 week after initiation
of therapy and at least monthly for the first 3 months.
8. Diarrhea or other causes of dehydration should be addressed emergently.
ACEIs indicates angiotensin converting enzyme inhibitors.
*Although the entry criteria for the trials of aldosterone antagonists included
creatinine greater than 2.5 mg per dl, the majority of patients had creatinine
much lower; in 1 trial (94), 95% of patients had creatinine less than or equal to
1.7 mg per dl.
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blocker class effect (98 –100). Patients who have Stage C HF
should be treated with 1 of these 3 beta-blockers. The relative
efficacy among these 3 agents is not known, but available
evidence does suggest that beta-blockers can differ in their
effects on survival (98).
EFFECT OF BETA-BLOCKERS IN THE MANAGEMENT OF HF
Beta-blockers have now been evaluated in more than
20 000 patients with HF who participated in more than 20
published placebo-controlled clinical trials (101,102). This
collective experience indicates that long-term treatment with
beta-blockers can lessen the symptoms of HF, improve the
clinical status of patients, and enhance the patient’s overall
sense of well-being (95,103–109). In addition, like ACEIs,
beta-blockers can reduce the risk of death and the combined
risk of death or hospitalization (95,110 –113).
PRACTICAL USE OF BETA-BLOCKERS: SELECTION OF PATIENTS
Because of its favorable effects on survival and disease
progression, treatment with a beta-blocker should be ini-
tiated as soon as LV dysfunction is diagnosed. Even when
symptoms are mild or have responded to other therapies,
beta-blocker therapy is important and should not be
delayed until symptoms return or disease progression is
documented during treatment with other drugs. Beta-
blockers may be considered in patients who have reactive
airway disease or asymptomatic bradycardia but should be
used with great caution or not at all in patients with
persistent symptoms of either condition.
INITIATION AND MAINTENANCE
Treatment with a beta-blocker should be initiated at very
low doses (see Table 5), followed by gradual increments in
dose if lower doses have been well tolerated. Recent data
show that beta-blockers can be safely started before dis-
charge, even in patients hospitalized for HF, provided they do
not require intravenous therapy for HF (114).
DIGITALIS
The Writing Committee has re-evaluated the evidence
pertinent to the value of digitalis therapy in patients with HF.
Although no new data or trials using digitalis have emerged
since publication of the 2001 guidelines, the Writing Com-
mittee believes that in terms of safety and efficacy, digitalis
does not compare favorably with such agents as the aldoste-
rone blockers, to which the Writing Committee has assigned
a Class IIa level of recommendation. If digitalis were a new
drug with clinical trials showing a very narrow risk/benefit
ratio (especially for potential use in the aging population) and
no mortality benefit, it would clearly not be considered for a
Class I recommendation. The Writing Committee, therefore,
decided to change the level of recommendation for digitalis
glycosides from Class I to Class IIa in the current document.
VENTRICULAR ARRHYTHMIAS AND PREVENTION OF
SUDDEN DEATH
Sudden death can be decreased meaningfully by the ther-
apies that decrease disease progression, as discussed else-
where in these guidelines, and by the use of implanted
devices that terminate sustained arrhythmias.
SECONDARY PREVENTION OF SUDDEN DEATH
Patients with previous cardiac arrest or documented sustained
ventricular arrhythmias have a high risk of recurrent events. Im-
plantation of an implantable cardioverter-defibrillator (ICD) has
been shown to reduce mortality in cardiac arrest survivors. An ICD
is indicated for secondary prevention of death due to ventricular
tachyarrhythmias in patients with otherwise good clinical function
and prognosis, for whom prolongation of survival is a goal. Patients
with chronic HF and a low EF who experience syncope of unclear
origin have a high rate of subsequent sudden death and should also
be considered for placement of an ICD (115). However, when
ventricular tachyarrhythmias occur in a patient with a progressive
and irreversible downward spiral of clinical HF decompensation,
placement of an ICD is not indicated to prevent recurrence of
sudden death, because death is likely imminent regardless of mode.
An exception may exist for the small minority of patients for whom
definitive therapy such as cardiac transplantation is planned.
PRIMARY PREVENTION OF SUDDEN DEATH
Patients with low EF without prior history of cardiac arrest,
spontaneous ventricular tachycardia (VT), or inducible VT
(positive programmed electrical stimulation study) have a risk of
sudden death that is lower than for those who have experienced
previous events, but it remains significant. Within this group, it
has not yet been possible to identify those patients at highest risk,
especially in the absence of prior MI.
Amiodarone has been associated with overall neutral effects on
survival when given to patients with low EF and HF (116 –119).
Amiodarone therapy may also act through mechanisms other than
antiarrhythmic effects, because amiodarone has been shown in
some trials to increase LVEF and decrease the incidence of
worsening HF (117,118). Side effects of amiodarone have included
thyroid abnormalities, pulmonary toxicity, hepatotoxicity, neuropa-
thy, insomnia, and numerous other reactions. Therefore, amiod-
arone should not be considered as part of the routine treatment of
patients with HF, with or without frequent premature ventricular
depolarizations or asymptomatic nonsustained VT; however, it
remains the agent most likely to be safe and effective when
antiarrhythmic therapy is necessary to prevent recurrent atrial
fibrillation or symptomatic ventricular arrhythmias. Other pharma-
cological antiarrhythmic therapies, apart from beta-blockers, are
rarely indicated in HF but may occasionally be used to suppress
recurrent ICD shocks when amiodarone has been ineffective or
discontinued owing to toxicity.
ROLE OF ICDS IN THE PRIMARY PREVENTION OF SUDDEN DEATH
The role of ICD implantation for the primary prevention of
sudden death in patients with HF and low EF and no history
of spontaneous or inducible VT has been addressed by
several large trials that used only readily available clinical
data as entry criteria (119 –121). ICDs are highly effective in
preventing death due to ventricular tachyarrhythmias; how-
ever, frequent shocks from an ICD can lead to a reduced
quality of life. For symptoms from recurrent discharges
triggered by ventricular arrhythmias or atrial fibrillation,
antiarrhythmic therapy, most often amiodarone, may be
added. For recurrent ICD discharges from VT despite antiar-
rhythmic therapy, catheter ablation may be effective (122).
It is important to recognize that ICDs have the potential to
aggravate HF and have been associated with an increase in
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HF hospitalizations (120,123). This may result from right
ventricular pacing that produces dyssynchronous cardiac
contraction; however, the occurrence of excess nonsudden
events with ICDs placed early after MI suggests that other
factors may also limit the overall benefit from ICDs. Careful
attention to the details of ICD implantation, programming,
and pacing function is important for all patients with low EF
who are treated with an ICD. The ACC/AHA/NASPE 2002
Guideline Update for Implantation of Cardiac Pacemakers
and Antiarrhythmia Devices (124) provides further discus-
sion of the potential problem of worsening HF and LV
function in all patients with right ventricular pacing.
The decision regarding the balance of potential risks and
benefits of ICD implantation for an individual patient thus
remains a complex one. A decrease in incidence of sudden death
does not necessarily translate into decreased total mortality, and
decreased total mortality does not guarantee a prolongation of
survival with meaningful quality of life. This concept is partic-
ularly important in patients with limited prognosis owing to
advanced HF or other serious comorbidities, because there was
no survival benefit observed from ICD implantation until after
the first year in 2 of the major trials (119,120).
c. Interventions to be Considered for Use in Selected
Patients
ISOSORBIDE DINITRATE
Isosorbide dinitrate was one of the first vasodilator agents
reported to be useful for chronic therapy of HF. Nitrate
therapy may decrease symptoms of dyspnea at night and
during exercise and may improve exercise tolerance in
patients who have persistent limitation despite optimization
of other therapies (125).
The only common side effects of nitrate therapy are
headaches and hypotension. In clinical use, nitrates are
frequently prescribed to patients with persistent congestive
symptoms. Although the only large trial of nitrates in HF
(125a) used a combination of nitrates and hydralazine,
nitrates predominantly are potent venodilators that also
have effects on arterial tone when used alone, particularly
when systemic vascular resistance is severely elevated.
Because they act through cyclic guanosine monophos-
phate, there is a theoretical reason that they may be titrated
up to facilitate weaning of intravenous infusions that act
through the same pathway.
HYDRALAZINE
There are limited data regarding the use of hydralazine
alone in HF.
HYDRALAZINE AND ISOSORBIDE DINITRATE
A post hoc retrospective analysis of 2 vasodilator trials demon-
strated particular efficacy of isosorbide dinitrate and hydralazine in
the black cohort (125b). A confirmatory trial has been done. In that
trial, which was limited to the black population with HF, the
addition of hydralazine and isosorbide dinitrate to therapy with an
ACEI and/or a beta-blocker was shown to be of significant benefit
(160). The benefit was presumed to be related to enhanced nitric
oxide bioavailability. Whether this benefit is evident in other
patients with HF remains to be investigated. The combination of
hydralazine and isosorbide dinitrate should not be used for the
treatment of HF in patients who have no prior use of an ACEI and
should not be substituted for ACEIs in patients who are tolerating
ACEIs without difficulty.
Despite the lack of data with the vasodilator combination
in patients who are intolerant of ACEIs, the combined use of
hydralazine and isosorbide dinitrate may be considered as a
therapeutic option in such patients. However, compliance
with this combination has generally been poor because of the
large number of tablets required and the high incidence of
adverse reactions (70,127). For patients with more severe
symptoms and ACEI intolerance, the combination of hydral-
azine and nitrates is used frequently, particularly when ACEI
therapy is limited by hypotension or renal insufficiency.
There are, however, no trials addressing the use of isosorbide
dinitrate and hydralazine specifically in the population of
patients who have persistent symptoms and intolerance to
inhibitors of the renin-angiotensin system.
CARDIAC RESYNCHRONIZATION THERAPY
To date, more than 4000 HF patients with ventricular dyssyn-
chrony have been evaluated in randomized controlled trials of
optimal medical therapy alone versus optimal medical therapy plus
cardiac resynchronization therapy with or without an ICD. Cardiac
resynchronization therapy, when added to optimal medical therapy
in persistently symptomatic patients, has resulted in significant
improvements in quality of life, functional class, exercise capacity,
exercise distance, EF, and survival in patients randomized to such
therapy (128) or to the combination of cardiac resynchronization
therapy and ICD (129 –131). The use of an ICD in combination
with cardiac resynchronization therapy should be based on the
indications for ICD therapy. Recommendations regarding cardiac
resynchronization therapy for patients with right bundle-branch
block, atrial fibrillation, minor conduction abnormality, and pace-
maker dependence as well as inadequate medical therapy must
await the completion of ongoing or future trials.
d. Drugs and Interventions Under Active Investigation
Several drugs that showed promise in pilot studies and were
included in this section in the 2001 guidelines failed to live up to
their promise in long-term, large-scale trials and are no longer
included as “promising” in this update. Several remain under or
have begun active investigation. Investigational drug therapies
currently in phase III evaluation for the treatment of chronic HF
include vasopressin receptor antagonists, intermittent nesiritide in-
fusions, and oral phosphodiesterase III inhibitors. In addition, newer
devices and technologies, such as implantable hemodynamic mon-
itors and internal cardiac support devices, external counterpulsation,
treatment for sleep-disordered breathing, myocardial growth factors
and stem cell transplantation, and devices to achieve intravascular
volume reduction, as well as novel surgical approaches, including
surgical ventricular restoration, are under active investigation.
e. Drugs and Interventions of Unproved Value and Not
Recommended
NUTRITIONAL SUPPLEMENTS AND HORMONAL THERAPIES
Aside from replenishment of documented deficiencies,
randomized trials have failed to demonstrate benefit for
routine vitamin supplementation (132). No clinical trials have
demonstrated improved survival in users of nutritional or
hormonal therapy.
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2. Patients With HF and Normal LVEF
RECOMMENDATIONS
CLASS I
1. Physicians should control systolic and diastolic hyperten-
sion in patients with HF and normal LVEF, in accordance
with published guidelines. (Level of Evidence: A)
2. Physicians should control ventricular rate in patients with
HF and normal LVEF and atrial fibrillation. (Level of
Evidence: C)
3. Physicians should use diuretics to control pulmonary con-
gestion and peripheral edema in patients with HF and
normal LVEF. (Level of Evidence: C)
CLASS IIA
1. Coronary revascularization is reasonable in patients with
HF and normal LVEF and coronary artery disease in whom
symptomatic or demonstrable myocardial ischemia is
judged to be having an adverse effect on cardiac function.
(Level of Evidence: C)
CLASS IIB
1. Restoration and maintenance of sinus rhythm in patients
with atrial fibrillation and HF and normal LVEF might be
useful to improve symptoms. (Level of Evidence: C)
2. The use of beta-adrenergic blocking agents, ACEIs, ARBs,
or calcium antagonists in patients with HF and normal
LVEF and controlled hypertension might be effective to
minimize symptoms of HF. (Level of Evidence: C)
3. The usefulness of digitalis to minimize symptoms of HF in
patients with HF and normal LVEF is not well established.
(Level of Evidence: C)
Table 7 summarizes the recommendations for treatment of
patients with HF and normal LVEF.
a. Identification of Patients
Over the past few years, there has been a growing appreciation
that a large number of patients with HF have a relatively normal EF,
or preserved EF. The pathophysiology of this type of HF has been
reviewed in depth (133), and a large, randomized study that enrolled
patients with HF and normal EF has been completed (134). Heart
failure associated with relatively preserved LVEF is most prevalent
among elderly women, most of whom have hypertension, diabetes
mellitus, or both and often coronary artery disease or atrial fibrilla-
tion as well (135).
A number of recent investigations have focused on the
differences between HF with preserved EF and that with low
LVEF (135a,136). Myocardial infarction or other evidence of
atherosclerotic disease appears to be less common in HF with
normal LVEF, but hypertension is at least as common in this
subgroup. The morbidity and mortality associated with HF
and a relatively preserved LVEF may be nearly as profound
as that with low LVEF; frequent and repeated hospitalizations
characterize the patient with HF and a normal LVEF
(137,138). Most, but not all, series of patients with HF and
relatively preserved LVEF have shown better survival than is
seen in patients with HF and reduced LVEF; however, these
comparisons are difficult to interpret, because it is difficult to
be certain that such series do not contain at least some
patients in whom the diagnosis of HF is erroneous.
b. Diagnosis
There have been several proposed criteria by which clinicians
and investigators may define HF with a relatively preserved LVEF
(139 –142). In general, a definitive diagnosis can be made when the
rate of ventricular relaxation is slowed; this physiological abnormal-
ity is characteristically associated with the finding of an elevated LV
TABLE 7. Recommendations for Treatment of Patients With
Heart Failure and Normal Left Ventricular Ejection Fraction
Recommendation Class Level of Evidence
Physicians should control systolic and
diastolic hypertension, in accordance with
published guidelines.
I A
Physicians should control ventricular rate in
patients with atrial fibrillation.
I C
Physicians should use diuretics to control
pulmonary congestion and peripheral edema.
I C
Coronary revascularization is reasonable in
patients with coronary artery disease in
whom symptomatic or demonstrable
myocardial ischemia is judged to be having
an adverse effect on cardiac function.
IIa C
Restoration and maintenance of sinus
rhythm in patients with atrial fibrillation
might be useful to improve symptoms.
IIb C
The use of beta-adrenergic blocking agents,
angiotensin converting enzyme inhibitors,
angiotensin II receptor blockers, or calcium
antagonists in patients with controlled
hypertension might be effective to minimize
symptoms of heart failure.
IIb C
The use of digitalis to minimize symptoms of
heart failure is not well established.
IIb C
TABLE 8. Differential Diagnosis in a Patient With Heart Failure
and Normal Left Ventricular Ejection Fraction
Incorrect diagnosis of HF





Episodic or reversible LV systolic dysfunction
Severe hypertension, myocardial ischemia
HF associated with high metabolic demand (high-output states)
Anemia, thyrotoxicosis, arteriovenous fistulae
Chronic pulmonary disease with right HF
Pulmonary hypertension associated with pulmonary vascular disorders
Atrial myxoma
Diastolic dysfunction of uncertain origin
Obesity
HF indicates heart failure; LV, left ventricular; and LVEF, left ventricular
ejection fraction.
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filling pressure in a patient with normal LV volumes and contrac-
tility. In practice, the diagnosis is generally based on the finding of
typical symptoms and signs of HF in a patient who is
shown to have a normal LVEF and no valvular abnormal-
ities (aortic stenosis or mitral regurgitation, for example)
on echocardiography. Every effort should be made to
exclude other possible explanations or disorders that may
present in a similar manner (144,145) (Table 8).
c. Principles of Treatment
In the absence of controlled clinical trials, the management
of these patients with HF and preserved LVEF is based on the
control of physiological factors (blood pressure, heart rate,
blood volume, and myocardial ischemia) that are known to
exert important effects on ventricular relaxation (144). Like-
wise, diseases that are known to cause HF with normal LVEF
should be treated, such as coronary artery disease, hyperten-
sive heart disease, or aortic stenosis. Clinically, it seems
reasonable to target symptom reduction, principally by reduc-
ing cardiac filling pressures at rest and during exertion (133).
D. Patients With Refractory End-Stage HF (Stage D)
RECOMMENDATIONS
CLASS I
1. Meticulous identification and control of fluid retention is
recommended in patients with refractory end-stage HF.
(Level of Evidence: B)
2. Referral for cardiac transplantation in potentially eligible
patients is recommended for patients with refractory end-
stage HF. (Level of Evidence: B)
3. Referral of patients with refractory end-stage HF to an HF
program with expertise in the management of refractory
HF is useful. (Level of Evidence: A)
4. Options for end-of-life care should be discussed with
the patient and family when severe symptoms in pa-
tients with refractory end-stage HF persist despite
application of all recommended therapies. (Level of
Evidence: C)
5. Patients with refractory end-stage HF and implantable
defibrillators should receive information about the op-
tion to inactivate defibrillation. (Level of Evidence: C)
CLASS IIA
1. Consideration of an LV assist device as permanent or
“destination” therapy is reasonable in highly selected
patients with refractory end-stage HF and an estimated
1-year mortality over 50% with medical therapy. (Level
of Evidence: B)
CLASS IIB
1. Pulmonary artery catheter placement may be reasonable to
guide therapy in patients with refractory end-stage HF and
persistently severe symptoms. (Level of Evidence: C)
2. The effectiveness of mitral valve repair or replacement is
not established for severe secondary mitral regurgitation in
refractory end-stage HF. (Level of Evidence: C)
3. Continuous intravenous infusion of a positive inotropic
agent may be considered for palliation of symptoms in
patients with refractory end-stage HF. (Level of Evidence:
C)
CLASS III
1. Partial left ventriculectomy is not recommended in patients
with nonischemic cardiomyopathy and refractory end-
stage HF. (Level of Evidence: C)
2. Routine intermittent infusions of positive inotropic agents
are not recommended for patients with refractory end-stage
HF. (Level of Evidence: B)
1. Management of Fluid Status
A critical step in the successful management of end-stage
HF is the recognition and meticulous control of fluid
retention.
2. Intravenous Peripheral Vasodilators and Positive
Inotropic Agents
Patients who cannot be weaned from intravenous to oral
therapy despite repeated attempts on multiple occasions may
require the continuous infusion of dobutamine or milrinone,
or as has been used more recently, nesiritide. Such a strategy
is commonly used in patients who are awaiting cardiac
transplantation, but it may also be used in the outpatient
setting in patients who are not being considered for trans-
plantation but who otherwise cannot be discharged from the
hospital. The decision to continue intravenous infusions at
home should not be made until all alternative attempts to
achieve stability have failed repeatedly, because such an
approach can present a major burden to the family and health
services and may ultimately increase the risk of death.
TABLE 9. Indications for Cardiac Transplantation
Absolute indications in appropriate patients
For hemodynamic compromise due to HF
Refractory cardiogenic shock
Documented dependence on IV inotropic support to maintain adequate
organ perfusion
Peak VO2 less than 10 ml per kg per min with achievement of
anaerobic metabolism
Severe symptoms of ischemia that consistently limit routine activity and
are not amenable to coronary artery bypass surgery or percutaneous
coronary intervention
Recurrent symptomatic ventricular arrhythmias refractory to all
therapeutic modalities
Relative indications
Peak VO2 11 to 14 ml per kg per min (or 55% of predicted) and major
limitation of the patient’s daily activities
Recurrent unstable ischemia not amenable to other intervention
Recurrent instability of fluid balance/renal function not due to patient
noncompliance with medical regimen
Insufficient indications
Low left ventricular ejection fraction
History of functional class III or IV symptoms of HF
Peak VO2 greater than 15 ml per kg per min (and greater than 55% of
predicted) without other indications
HF indicates heart failure; IV, intravenous; and VO2, oxygen consumption per
unit time.
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However, continuous intravenous inotropic support can pro-
vide palliation of symptoms as part of an overall plan to allow
the patient to die with comfort at home (146,147). The use of
continuous intravenous inotropic support to allow hospital
discharge should be distinguished from the intermittent ad-
ministration of infusions of such positive inotropic agents to
patients who have been successfully weaned from inotropic
support.
3. Mechanical and Surgical Strategies
Cardiac transplantation is currently the only established
surgical approach to the treatment of refractory HF, but it is
available to fewer than 2500 patients in the United States
each year (148,149). Current indications for cardiac trans-
plantation focus on the identification of patients with severe
functional impairment or dependence on intravenous inotro-
pic agents (Table 9). Alternate surgical and mechanical
approaches for the treatment of end-stage HF are under
development. Hemodynamic and clinical improvement has
been reported after mitral valve repair or replacement in
patients who have a clinically important degree of mitral
regurgitation that is secondary to LV dilatation (150). How-
ever, no controlled studies have evaluated the effects of this
procedure on ventricular function, clinical status, or survival.
A variant of the aneurysmectomy procedure is now being
developed for the management of patients with ischemic
cardiomyopathy (151), but its role in the management of HF
remains to be defined. None of the current surgical recon-
struction techniques offer “rescue therapy” to patients with
critical hemodynamic compromise. The use of mechanical
circulatory assist devices in end-stage HF is an area of intense
investigation. A recent trial provided evidence that non–
transplant-eligible patients requiring continuous intravenous
inotropic infusions could derive benefit from permanent
implantation of an LV device.
V. Treatment of Special Populations
RECOMMENDATIONS
CLASS I
1. Groups of patients including (a) high-risk ethnic mi-
nority groups (e.g., blacks), (b) groups underrepresent-
ed in clinical trials, and (c) any groups believed to be
underserved should, in the absence of specific evidence
to direct otherwise, have clinical screening and therapy
in a manner identical to that applied to the broader
population. (Level of Evidence: B)
2. It is recommended that evidence-based therapy for HF
be used in the elderly patient, with individualized
consideration of the elderly patient’s altered ability to
metabolize or tolerate standard medications. (Level of
Evidence: C)
CLASS IIA
1. The addition of isosorbide dinitrate and hydralazine to
a standard medical regimen for HF, including ACEIs
and beta-blockers, is reasonable and can be effective in
blacks with NYHA functional class III or IV HF.
Others may benefit similarly, but this has not yet been
tested. (Level of Evidence: A)
Many patients with HF are members of subpopulations
who are likely to exhibit unique responses that accelerate the
development or progression of HF or complicate the man-
agement of HF.
A. Women and Men
Most large, multicenter trials have not included sufficient
numbers of women to allow conclusions about the efficacy
and safety of their treatment. The conflicting data regarding
the efficacy of digoxin in women suggests that if it is
prescribed, particular attention should be paid to dosing and
renal function
B. Ethnic Considerations
Race is an imprecise concept that has largely become a
social and political construct with more limited biological
significance (152). The concept of racial “minorities” may be
relevant to large populations, especially those in clinical
trials, but is clearly not a concept applicable in many
demographic areas and clinical practices. However, it is
useful to review epidemiological and clinical trial evidence to
raise awareness of potential areas of concern and guide
socioeconomic and clinical remedies. Heart failure has a 50%
higher incidence in the black population than is seen in the
general population. Deficiencies in cardiovascular risk factor
and disease detection and treatment as well as in access to
quality outpatient care may contribute to the increased inci-
dence and morbidity of blacks with HF (153–155). Blacks
and other racial minorities with HF are underrepresented in
most clinical trials of new drugs for HF, which compromises
the extrapolation of results from major clinical trials to ethnic
subgroup populations.
The emerging field of genomic medicine has begun to
suggest that important variances in the expression of certain
high-risk, single-nucleotide polymorphisms may be evident
along racial lines and may provide a physiological basis for
differences in the natural history of HF and differences in
drug responsiveness (156 –159). Data from these early inves-
tigations are not yet definitive; racial groupings are necessar-
ily heterogenous, and data will need to be interpreted
cautiously.
A prospective, double-blind, randomized trial conducted
specifically in blacks with NYHA class III/IV HF has been
completed. In this trial, the adjunctive use of a proprietary
formulation of isosorbide dinitrate and hydralazine along
with a standard HF regimen resulted in a 43% decrease in
total mortality, which led to premature termination of the
trial. Additionally, time to first hospitalization and quality of
life were both improved (160).
C. Elderly Patients
The prevalence of HF rises from 2% to 3% at age 65 to
more than 80% in persons over 80 years of age. Heart failure
in elderly patients is inadequately recognized and treated
(161). Both patients and physicians frequently attribute the
symptoms of HF to aging, and noninvasive cardiac imaging
commonly fails to reveal impaired systolic function because
HF with a preserved LVEF is frequently found in the elderly.
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1. All other recommendations should apply to patients
with concomitant disorders unless there are specific
exceptions. (Level of Evidence C)
2. Physicians should control systolic and diastolic hypertension
and diabetes mellitus in patients with HF in accordance with
recommended guidelines. (Level of Evidence: C)
3. Physicians should use nitrates and beta-blockers for the
treatment of angina in patients with HF. (Level of Evi-
dence: B)
4. Physicians should recommend coronary revascularization
according to recommended guidelines in patients who
have both HF and angina. (Level of Evidence: A)
5. Physicians should prescribe anticoagulants in patients with
HF who have paroxysmal or persistent atrial fibrillation or
a previous thromboembolic event. (Level of Evidence: A)
6. Physicians should control the ventricular response rate in
patients with HF and atrial fibrillation with a beta-blocker
(or amiodarone, if the beta-blocker is contraindicated or
not tolerated). (Level of Evidence: A)
7. Patients with coronary artery disease and HF should be
treated in accordance with recommended guidelines for
chronic stable angina. (Level of Evidence: C)
8. Physicians should prescribe antiplatelet agents for pre-
vention of MI and death in patients with HF who have
underlying coronary artery disease. (Level of Evidence:
B)
CLASS IIA
1. It is reasonable to prescribe digitalis to control the ventric-
ular response rate in patients with HF and atrial fibrillation.
(Level of Evidence: A)
2. It is reasonable to prescribe amiodarone to decrease
recurrence of atrial arrhythmias and to decrease recur-
rence of ICD discharge for ventricular arrhythmias
(Level of Evidence: C)
CLASS IIB
1. The usefulness of current strategies to restore and
maintain sinus rhythm in patients with HF and atrial
fibrillation is not well established. (Level of Evidence: C)
2. The usefulness of anticoagulation is not well established in
patients with HF who do not have atrial fibrillation or a
previous thromboembolic event. (Level of Evidence: B)
3. The benefit of enhancing erythropoiesis in patients with
HF and anemia is not established. (Level of Evidence C)
CLASS III
1. Class I or III antiarrhythmic drugs are not recommended in
patients with HF for the prevention of ventricular arrhyth-
mias. (Level of Evidence: A)
2. The use of antiarrhythmic medication is not indicated
as primary treatment for asymptomatic ventricular
arrhythmias or to improve survival in patients with HF.
(Level of Evidence: A)
A. Cardiovascular Disorders
1. Hypertension, Hyperlipidemia, and Diabetes Mellitus
Heart failure may complicate the management of both
hypertension and diabetes mellitus. Some antihypertensive
agents should be avoided in patients with HF because of
their ability to depress cardiac function or to lead to salt
and water retention. Thiazolidinediones have been associ-
ated with increased peripheral edema and symptomatic HF
in patients with underlying risk factors or known cardio-
vascular disease. The risk of developing edema with
thiazolidinediones is dose related and is higher in diabetic
patients who are taking concomitant insulin therapy. How-
ever, the incidence of thiazolidinedione-related fluid re-
tention is low in patients with NYHA functional class I to
II symptoms, in whom these drugs can be administered
safely with careful monitoring for fluid retention. Initiation
of these drugs is not recommended in patients with NYHA
functional class III to IV symptoms of HF (162).
2. Supraventricular Arrhythmias
Supraventricular tachyarrhythmias may exert adverse ef-
fects by 4 different mechanisms: 1) the loss of atrial enhance-
ment of ventricular filling may compromise cardiac output; 2)
the rapid heart rate may increase demand and decrease
coronary perfusion (by shortening ventricular filling time); 3)
the rapidity of ventricular response may diminish both car-
diac contraction (by aggravating abnormalities of the force-
frequency relation) (163,164) and cardiac relaxation
(165,166); and 4) the stasis of blood in the fibrillating atria
may predispose patients to pulmonary or systemic emboli.
Specific care and initially low doses should be used when
instituting beta-blockers to control heart rate in patients with
clinical evidence of HF decompensation.
The efficacy and safety of restoring and maintaining sinus
rhythm in patients with atrial fibrillation was recently evalu-
ated in 4 separate trials (167). These trials consistently
showed no improvement in mortality or morbidity using a
strategy of aggressive rhythm control. However, the rate-
control strategy was associated with fewer hospitalizations
and fewer side effects from drug therapy. Until more defin-
itive data are available, treatment must be individualized.
3. Prevention of Thromboembolic Events
A randomized trial comparing the outcome of patients with
HF and low EF assigned to aspirin, warfarin, or clopidogrel
was completed recently. Unfortunately, low enrollment in the
trial precluded definitive conclusions about efficacy, but no
therapy appeared to be superior. Another trial is currently
under way comparing aspirin with warfarin in patients with
reduced LVEF and may provide more definitive data upon
which to base recommendations.
B. Noncardiovascular Disorders
1. Patients With Pulmonary Disease
Some drugs used to treat HF can produce or exacerbate
pulmonary symptoms. ACEIs can cause a persistent nonprod-
uctive cough that can be confused with a respiratory infection,
and conversely, ACEIs may be inappropriately stopped in
patients with pulmonary causes of cough. Therefore, physicians
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should seek a pulmonary cause in all patients with HF who
complain of cough, whether or not they are taking an ACEI.
Because the ACEI-related cough does not represent any serious
pathology, many patients can be encouraged to tolerate it in view
of the important beneficial effects of ACEI. Beta-blockers can
aggravate bronchospastic symptoms in patients with asthma;
however, many patients with asymptomatic or mild reactive
airway disease tolerate beta-blockers well.
2. Patients With Cancer
Heart failure may appear many years after anthracycline
exposure, particularly in association with another stress, such
as tachycardia. Although once thought to progress inexora-
bly, HF related to chemotherapy often improves in response
to therapy, even when it appears late after exposure.
3. Patients With Thyroid Disease
Special vigilance is required for patients taking amiod-
arone, who may develop either hyperthyroidism or hypothy-
roidism. New atrial fibrillation or exacerbation of ventricular
arrhythmias should trigger re-evaluation of thyroid status.
4. Patients With Hepatitis C and Human
Immunodeficiency Virus
Hepatitis C viral infection can be a cause of cardiomyopathy and
myocarditis A small study showed that hepatitis C virus myocarditis
might respond favorably to immunosuppressive therapy with pred-
nisone and azathioprine (168,169). Preliminary data also suggest
that hepatitis C virus myocarditis might respond well to interferon
therapy (170), although there is concern that interferon can also
depress myocardial function.
Human immunodeficiency virus has been recognized as a
probable occasional cause of dilated cardiomyopathy. Be-
cause of the occurrence of complex opportunistic infections,
autoimmune responses to the viral infection, and drug car-
diotoxicity, it is difficult to determine how therapies influence
the development and control of cardiomyopathy with human
immunodeficiency virus (171).
5. Patients With Anemia
Patients with HF frequently have anemia for a variety of
reasons. The severity of anemia may contribute to the
increasing severity of HF. Several studies have demonstrated
worse patient outcomes in patients with HF and anemia
(172,173). It is unclear whether anemia is the cause of
decreased survival or a result of more severe disease.
VII. End-of Life Considerations
RECOMMENDATIONS
CLASS I
1. Ongoing patient and family education regarding prognosis
for functional capacity and survival is recommended for
patients with HF at the end of life. (Level of Evidence: C)
2. Patient and family education about options for formulating
and implementing advance directives and the role of
palliative and hospice care services with re-evaluation
for changing clinical status is recommended for patients
with HF at the end of life. (Level of Evidence: C)
3. Discussion is recommended regarding the option of
inactivating ICDs for patients with HF at the end of life.
(Level of Evidence: C)
4. It is important to ensure continuity of medical care between
inpatient and outpatient settings for patients with HF at the
end of life. (Level of Evidence: C)
5. Components of hospice care that are appropriate to the
relief of suffering, including opiates, are recommended
and do not preclude the options for use of inotropes and
intravenous diuretics for symptom palliation for pa-
tients with HF at the end of life. (Level of Evidence: C)
6. All professionals working with HF patients should
examine current end-of-life processes and work toward
improvement in approaches to palliation and end-of-
life care. (Level of Evidence: C)
CLASS III
1. Aggressive procedures performed within the final days
of life (including intubation and implantation of a
cardioverter-defibrillator in patients with NYHA func-
tional class IV symptoms who are not anticipated to
experience clinical improvement from available treat-
ments) are not appropriate. (Level of Evidence: C)
The patient should be encouraged to choose in advance a
person to assume legal authority (i.e., designated power of
attorney or healthcare proxy) for healthcare matters when the
patient cannot be involved in decisions. That individual
should serve as the contact point for the team. Professionals
caring for patients with advanced HF should have realistic
expectations for survival and communicate those accurately
to patients and families. Also, the professionals should
provide realistic recommendations for procedures being done
within the final days of life that do not add to the hope of
recovery or improvement in life quality. Finally, greater
attention and research need to be devoted to the provision of
comfort measures in the final days of life, including relief of
pain and dyspnea.
Ultimately, the decisions regarding when end of life is
nearing reflect a complex interaction between objective
information and subjective information, emotions, and
patient and family readiness. Ideally, these decisions
would be made in conjunction with the individual or team
most experienced in caring for advanced HF or in collab-
oration and/or consultation with such an expert. In reality,
however, this does not occur often. The Writing Commit-
tee recommends that all those involved with HF care make
it a priority to improve recognition of end-stage disease
and provide care to patients and families approaching this
stage. As we become more familiar with the steps in
progression to end-stage HF in this era, the current abrupt
transition from aggressive intervention to comfort and
bereavement care will be softened by a gradual and
progressive emphasis on palliation until it dominates the
final days of care (174).
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VIII. Implementation of Practice Guidelines
RECOMMENDATIONS
CLASS I
1. Academic detailing or educational outreach visits are
useful to facilitate the implementation of practice guide-
lines. (Level of Evidence: A)
2. Multidisciplinary disease-management programs for pa-
tients at high risk for hospital admission or clinical deteri-
oration are recommended to facilitate the implementation
of practice guidelines, attack different barriers to behav-
ioral change, and reduce the risk of subsequent hospi-
talization for HF. (Level of Evidence: A)
CLASS IIA
1. Chart audit and feedback of results can be effective to
facilitate implementation of practice guidelines. (Level of
Evidence: A)
2. The use of reminder systems can be effective to facilitate
implementation of practice guidelines. (Level of Evidence:
A)
3. The use of performance measures based on practice
guidelines may be useful to improve quality of care.
(Level of Evidence: B)
4. Statements by and support of local opinion leaders can
be helpful to facilitate implementation of practice guide-
lines. (Level of Evidence: A)
CLASS IIB
1. Multidisciplinary disease-management programs for pa-
tients at low risk for hospital admission or clinical deteri-
oration may be considered to facilitate implementation of
practice guidelines. (Level of Evidence: B)
CLASS III
1. Dissemination of guidelines without more intensive behav-
ioral change efforts is not useful to facilitate implementa-
tion of practice guidelines. (Level of Evidence: A)
2. Basic provider education alone is not useful to facilitate
implementation of practice guidelines. (Level of Evidence:
A)
Performance Measures
Performance measures are standards of care for a particular
illness or condition that are designed to assess and subse-
quently improve the quality of medical care and are chosen
on the basis of the knowledge or assumption that the
particular item is linked to improved patient outcomes. The
ACC and AHA are collaborating with a variety of organiza-
tions to develop and implement performance measures.
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